Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 32
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical value of plasma pTau181 to predict Alzheimer's disease pathology in a large real-world cohort of a memory clinic

  • Cano, Amanda|||0000-0001-9567-4283
  • Capdevila, María
  • Puerta, Raquel|||0000-0002-1191-5893
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • De Rojas, Itziar|||0000-0002-2148-381X
  • García-González, Pablo|||0000-0003-0125-5403
  • Olivé Roig, Clàudia|||0000-0002-9438-5639
  • García-Gutiérrez, Fernando
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Aguilera, Nuria
  • Ramis, Maribel
  • Rosende-Roca, Maite
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Tartari, Juan Pablo
  • Lafuente, Asunción
  • Vargas, Liliana|||0000-0001-5685-5903
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Muñoz, Nathalia
  • Sanabria, Ángela|||0000-0002-7501-9895
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Morató, Xavier|||0000-0002-3012-2864
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Fernández, Victoria
  • Marquié, Marta|||0000-0002-0660-0950
  • Valero, Sergi|||0000-0002-6599-948X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
The identification of patients with an elevated risk of developing Alzheimer's disease (AD) dementia and eligible for the disease-modifying treatments (DMTs) in the earliest stages is one of the greatest challenges in the clinical practice. Plasma biomarkers has the potential to predict these issues, but further research is still needed to translate them to clinical practice. Here we evaluated the clinical applicability of plasma pTau181 as a predictive marker of AD pathology in a large real-world cohort of a memory clinic. Methods: Three independent cohorts (modelling [n = 991, 59.7% female], testing [n = 642, 56.2% female] and validation [n = 441, 55.1% female]) of real-world patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), AD dementia, and other dementias were included. Paired cerebrospinal fluid (CSF) and plasma samples were used to measure AT(N) CSF biomarkers and plasma pTau181. CSF and plasma pTau181 showed correlation in all phenotypes except in SCD and other dementias. Age significantly influenced the biomarker's performance. The general Aβ(+) vs Aβ(-) ROC curve showed an AUC = 0.77 [0.74-0.80], whereas the specific ROC curve of MCI due to AD vs non-AD MCI showed an AUC = 0.89 [0.85-0.93]. A cut-off value of 1.30 pg/ml of plasma pTau181 exhibited a sensitivity of 93.57% [88.72-96.52], specificity of 72.38% [62.51-79.01], VPP of 77.85% [70.61-83.54], and 8.30% false negatives in the subjects with MCI of the testing cohort. The HR of cox regression showed that patients with MCI up to this cut-off value exhibited a HR = 1.84 [1.05-3.22] higher risk to convert to AD dementia than patients with MCI below the cut-off value. Plasma pTau181 has the potential to be used in the memory clinics as a screening biomarker of AD pathology in subjects with MCI, presenting a valuable prognostic utility in predicting the MCI conversion to AD dementia. In the context of a real-world population, a confirmatory test employing gold-standard procedures is still advisable. This study has been mainly funded by Ace Alzheimer Center Barcelona, Instituto de Salud Carlos III (ISCIII), Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Spanish Ministry of Science and Innovation, Fundación ADEY, Fundación Echevarne and Grífols S.A.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Amyloid deposition in adults with drug-resistant temporal lobe epilepsy

  • Fonseca, Elena|||0000-0002-3895-1237
  • Lallana, Sofía|||0000-0002-5999-9889
  • Ortega, Gemma
  • Cano, Amanda|||0000-0001-9567-4283
  • Sarria Estrada, Silvana|||0000-0003-0083-362X
  • Pareto, Deborah|||0000-0001-7356-3769
  • Quintana, Manuel|||0000-0003-0288-9088
  • Lorenzo Bosquet, Carles|||0000-0002-8824-4602
  • López Maza, Samuel|||0000-0003-3660-2604
  • Gifreu, Ariadna
  • Campos Fernández, Daniel|||0000-0003-4795-5309
  • Abraira del Fresno, Laura|||0000-0002-5119-7929
  • Santamarina Perez, Estevo|||0000-0003-1915-0335
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Puerta, Raquel|||0000-0002-1191-5893
  • Aguilera, Núria
  • Ramis, Maribel
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Rovira, Alex|||0000-0002-2132-6750
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Toledo, Manuel|||0000-0003-1550-3316
Objective: Pathological amyloid-β (Aβ) accumulation and hyperphosphorylated tau proteins have been described in resected temporal lobe specimens of epilepsy patients. We aimed to determine cerebrospinal fluid (CSF) Aβ1-42 and p181-tau levels and cerebral Aβ deposits on positron emission tomography (Aβ PET) and correlate these findings with cognitive performance in adults with drug-resistant temporal lobe epilepsy (TLE). Methods: In this cross-sectional study, we enrolled individuals with drug-resistant TLE who were 25-55 years old. Each participant underwent F-flutemetamol PET, determination of CSF Aβ1-42, p181-tau, and total tau, and a comprehensive neuropsychological assessment. We evaluated normalized standard uptake value ratios (SUVRs) for different brain regions on Aβ PET. Results: Thirty patients (mean age = 41.9 ± SD 8.1 years, 57% men) were included. The median disease duration was 9.5 (interquartile range = 4-24) years. Twenty-six patients (87%) had a clinically significant cognitive impairment on neuropsychological evaluation, 18 (69%) of the amnesic type. On Aβ PET, high uptake was observed in both mesial temporal regions (ipsilateral: SUVR z-score =.90, 95% confidence interval [CI] =.60-1.20; contralateral: SUVR z-score =.92, 95% CI =.57-1.27; p <.001), which was higher when compared to SUVR z-scores in all the remaining regions (p <.001) and in the ipsilateral anterior cingulate (SUVR z-score =.27, 95% CI =.04-.49, p =.020). No significant deposition was observed in other regions. Seven patients (23%) had low Aβ1-42 levels, and two (7%) had elevated p181-tau levels in CSF. Higher p181-tau levels correlated with poorer verbal fluency (R = -.427, p =.044). Significance: Our findings reveal a considerable Aβ deposition in mesial temporal regions and ipsilateral anterior cingulate among adults with drug-resistant TLE. Additionally, abnormal CSF Aβ1-42 levels were observed in a significant proportion of patients, and p181-tau levels were associated with verbal fluency. These results suggest that markers of neuronal damage can be observed in adults with TLE, warranting further investigation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Associations of lifestyle factors with amyloid pathology in persons without dementia

  • Vos, Stephanie J.B.|||0000-0002-2045-9818
  • Boada, Mercè|||0000-0003-2617-3009
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Fladby, Tormod|||0000-0002-9984-9797
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Frisoni, Giovanni B.|||0000-0002-6419-1753
  • Grimmer, Timo
  • Hort, Jakub|||0000-0002-1080-3726
  • Iwatsubo, Takeshi
  • Klimkowicz-Mrowiec, Aleksandra
  • Landau, Susan M.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Martinez-Lage, Pablo|||0000-0001-5404-9967
  • de Mendonça, Alexandre|||0000-0002-0488-1453
  • Parchi, Piero
  • Pardini, Matteo
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Popp, Julius|||0000-0002-0068-0312
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Santana, Isabel|||0000-0002-8114-9434
  • Scarmeas, Nikolaos|||0000-0001-6453-8908
  • Scheltens, Philip|||0000-0002-1046-6408
  • Skoog, Ingmar
  • Sperling, Reisa A.
  • Stern, Yaakov
  • Villeneuve, Sylvia
  • Waldemar, Gunhild
  • Wiltfang, Jens
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Bateman, Randall J.
  • Blennow, Kaj|||0000-0002-1890-4193
  • Chipi, Elena
  • Fortea, Juan|||0000-0002-1340-638X
  • Freund-Levi, Yvonne|||0000-0001-6863-6679
  • Handels, Ron
  • Hausner, Lucrezia|||0000-0001-9009-2356
  • Kern, Silke
  • Kornhuber, Johannes|||0000-0002-8096-3987
  • Legdeur, Nienke
  • Levin, Johannes|||0000-0001-5092-4306
  • Maier, Wolfgang
  • Marquié, Marta|||0000-0002-0660-0950
  • Mroczko, Barbara
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Peters, Oliver|||0000-0003-0568-2998
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Selnes, Per
  • Soininen, Hilkka|||0000-0002-2785-9937
  • Spiru, Luiza
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Tijms, Betty M.|||0000-0002-2612-1797
  • Vermunt, Lisa
  • Wallin, Åsa K.
  • Yannakoulia, Mary
  • Zettergren, Anna|||0000-0002-7182-8417
  • Ossenkoppele, Rik
  • Visser, Pieter Jelle|||0000-0001-8008-9727
  • Jansen, Willemijn J.
  • Oomens, Julie E.
  • Maserejian, Nancy N.
  • Didic, Mira
  • Fröhlich, Lutz
  • Dip Gill, Kiran
  • Itoh, Yoshiaki
  • Lee, Dong Young
  • Meyer, Philipp T.
  • Reiman, Eric M.
  • Rinne, Juha O.
  • Rodrigue, Karen M.
  • Allegri, Ricardo F.
  • Altomare, Daniele
  • Baiardi, Simone
  • Baldeiras, Inês|||0000-0002-8106-7308
  • den Braber, Anouk
  • van Buchem, Mark A.
  • Byun, Min Soo
  • Cerman, Jiří
  • Chen, Kewei
  • Day, Gregory S.
  • Drzezga, Alexander
  • Ekblad, Laura L.
  • Förster, Stefan
  • Frings, Lars
  • Guedj, Eric
  • Habeck, Christian G.
  • Hellwig, Sabine
  • Jiménez-Bonilla, Julio F.
  • Iriondo Juaristi, Ane
  • Kandimalla, Ramesh
  • Bordewick Kirsebom, Bjørn Eivind S.
  • Minatani, Shinobu
  • Morbelli, Silvia Daniela
  • Ntanasi, Eva
  • Resende de Oliveira, Catarin
  • Prabhakar, Sudesh
  • Ramakers, Inez H.
  • Rodríguez-Rodriguez, Eloy
  • Rüther, Eckart
  • Sakhardande, Jayant
  • Silva, Dina
  • Takeda, Akitoshi
  • Wiels, Wietse
  • Yi, Dahyun
  • Verhey, Frans R.J.
Background: The association between lifestyle factors and Alzheimer's disease (AD) pathophysiology remains incompletely understood. Objective: The aim of this study was to assess the association of alcohol consumption, smoking behavior, sleep quality and physical, cognitive, and social activity with cerebral amyloid pathology. Methods: For this cross-sectional study, we selected participants from the Amyloid Biomarker Study data pooling initiative. We used generalized estimating equations to assess associations of dichotomized lifestyle measures with amyloid pathology. Results: We included 9171 participants with normal cognition (NC) and 2555 participants with mild cognitive impairment (MCI) from the Amyloid Biomarker Study. Of participants with NC, 58% were women, 34% were APOE ε4 carrier, and 27% had amyloid pathology. Of participants with MCI, 48% were women, 47% were APOE ε4 carrier, and 57% had amyloid pathology. In NC, cognitively active participants were less likely to have amyloid pathology (OR = 0.77, 95%CI 0.66-0.89, p < 0.001). In MCI, participants who had ever smoked or had sleep problems were less likely to have amyloid pathology (OR = 0.85, 95%CI 0.73-0.99, p = 0.029; OR = 0.62, 95%CI 0.45-0.86, p = 0.004). Conclusions: In NC, cognitive activity was associated with a lower frequency of amyloid pathology. In MCI, favorable lifestyle behaviors were not associated with a lower frequency of amyloid pathology. The results of the current study contribute to the broader evidence base on lifestyle and AD by further characterizing the role of lifestyle behaviors in AD pathology across different clinical stages.
Repisalud
Publicación Artículo científico (JournalArticle)

Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GRaACE project.

  • Moreno-Grau, Sonia
  • de Rojas, Itziar
  • Hernández, Isabel
  • Quintela, Inés
  • Montrreal, Laura
  • Alegret, Montserrat
  • Hernández-Olasagarre, Begoña
  • Madrid, Laura
  • González-Pérez, Antonio
  • Maroñas, Olalla
  • Rosende-Roca, Maitée
  • Mauleón, Ana
  • Vargas, Liliana
  • Lafuente, Asunción
  • Abdelnour, Carla
  • Rodríguez-Gómez, Octavio
  • Gil, Silvia
  • Santos-Santos, Miguel Ángel
  • Espinosa, Ana
  • Ortega, Gemma
  • Sanabria, Ángela
  • Pérez-Cordón, Alba
  • Cañabate, Pilar
  • Moreno, Mariola
  • Preckler, Silvia
  • Ruiz, Susana
  • Aguilera, Nuria
  • Pineda, Juan Antonio
  • Macías, Juan
  • Alarcón-Martín, Emilio
  • Sotolongo-Grau, Oscar
  • Marquié, Marta
  • Monté-Rubio, Gemma
  • Valero, Sergi
  • Benaque, Alba
  • Clarimón, Jordi
  • Bullido, María Jesús
  • Garcia-Ribas, Guillermo
  • Pástor, Pau
  • Sánchez-Juan, Pascual
  • Álvarez, Victoria
  • Piñol-Ripoll, Gerard
  • García-Alberca, Jose María
  • Royo, José Luis
  • Franco, Emilio
  • Mir, Pablo
  • Calero, Miguel
  • Medina, Miguel
  • Rábano, Alberto
  • Ávila, Jesús
  • Antúnez, Carmen
  • Real, Luis Miguel
  • Orellana, Adelina
  • Carracedo, Ángel
  • Sáez, María Eugenia
  • Tárraga, Lluís
  • Boada, Mercè
  • Ruiz, Agustín
Introduction: Large variability among Alzheimer's disease (AD) cases might impact genetic discoveries and complicate dissection of underlying biological pathways. Methods: Genome Research at Fundacio ACE (GR@ACE) is a genome-wide study of dementia and its clinical endophenotypes, defined based on AD's clinical certainty and vascular burden. We assessed the impact of known AD loci across endophenotypes to generate loci categories. We incorporated gene coexpression data and conducted pathway analysis per category. Finally, to evaluate the effect of heterogeneity in genetic studies, GR@ACE series were meta-analyzed with additional genome-wide association study data sets. Results: We classified known AD loci into three categories, which might reflect the disease clinical heterogeneity. Vascular processes were only detected as a causal mechanism in probable AD. The meta-analysis strategy revealed the ANKRD31-rs4704171 and NDUFAF6-rs10098778 and confirmed SCIMP-rs7225151 and CD33-rs3865444. Discussion: The regulation of vasculature is a prominent causal component of probable AD. GR@ACE meta-analysis revealed novel AD genetic signals, strongly driven by the presence of clinical heterogeneity in the AD series.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Design and Processing as Ultrathin Films of a Sublimable Iron(II) Spin Crossover Material Exhibiting Efficient and Fast Light-Induced Spin Transition

  • Gavara-Edo, Miguel
  • Valverde-Muñoz, Francisco Javier
  • Moubtassim, Safaa Elidrissi
  • Marques-Moros, Francisco
  • Herrero-Martín, Javier
  • Znovjyak, Kateryna
  • Seredyuk, Maksym
  • Real, José Antonio
  • Coronado, Eugenio
  • Muñoz Roca, María Del Carmen|||0000-0003-2630-3897
[EN] Materials based on spin crossover (SCO) molecules have centered the attention in molecular magnetism for more than 40 years as they provide unique examples of multifunctional and stimuli-responsive materials, which can be then integrated into electronic devices to exploit their molecular bistability. This process often requires the preparation of thermally stable SCO molecules that can sublime and remain intact in contact with surfaces. However, the number of robust sublimable SCO molecules is still very scarce. Here, we report a novel example of this kind. It is based on a neutral iron(II) coordination complex formulated as [Fe(neoim)(2)], where neoimH is the ionogenic ligand 2-(1H-imidazol-2-yl)-9-methyl-1,10-phenanthroline. In the first part, a comprehensive study, which covers the synthesis and magnetostructural characterization of the [Fe(neoim)(2)] complex as a bulk microcrystalline material, is reported. Then, in the second part, we investigate the suitability of this material to form thin films through high-vacuum sublimation. Finally, the retainment of all present SCO capabilities in the bulk when the material is processed is thoroughly studied by means of X-ray absorption spectroscopy. In particular, a very efficient and fast light-induced spin transition (LIESST effect) has been observed, even for ultrathin films of 15 nm., M.G.-E. acknowledges the support of a fellowship FPU15/01474 from MIU. F.J.V.-M. acknowledges the support of the Generalitat Valenciana (APOSTD/2021/359). S.E.M. acknowledges the support of the Generalitat Valenciana with a Santiago Grisolia fellowship (GRISOLIAP/2018/046). All XAS experiments were performed at Boreas beamline at ALBA Synchrotron with J.H.-M. in both proposal and in-house experiments. The authors thank Alejandra Soriano Portillo and Angel Lopez Munoz for their technical support.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mendelian Randomisation Confirms the Role of Y-Chromosome Loss in Alzheimer’s Disease Aetiopathogenesis in Men

  • García-González, Pablo
  • Rojas, Itziar de
  • Moreno-Grau, Sonia
  • Montrreal, Laura
  • Puerta, Raquel
  • Alarcón-Martín, Emilio
  • Quintela, Inés
  • Orellana, Adela
  • Andrade, Victor
  • Martino-Adami, Pamela V.
  • Heilmann-Heimbach, Stefanie
  • Gómez-Garre, Pilar
  • Periñán, María Teresa
  • Álvarez, Ignacio
  • Díez-Fairen, Mónica
  • Nuñez-Llaves, Raul
  • Olivé-Roig, Claudia
  • García-Ribas, Guillermo
  • Menéndez-González, Manuel
  • Martínez, Carmen
  • Aguilar Barberá, Miquel
  • Buongiorno, Maria Teresa
  • Franco-Macías, Emilio
  • Sáez, María Eugenia
  • Cano, Amanda
  • Bullido, María Jesús
  • Real, Luis Miguel
  • Rodríguez-Rodríguez, Eloy
  • Royo, José Luis
  • Álvarez, Victoria
  • Pastor, Pau
  • Piñol-Ripoll, Gerard
  • Mir, Pablo
  • Calero, Miguel
  • Medina-Padilla, Miguel
  • Sánchez-Juan, Pascual
  • Carracedo, Ángel
  • Valero, Sergi
  • Hernández, Isabel
  • Tárraga, Lluís
  • Ramírez, Alfredo
  • Boada, Mercè
  • Ruiz, Agustín
Mosaic loss of chromosome Y (mLOY) is a common ageing-related somatic event and has been previously associated with Alzheimer’s disease (AD). However, mLOY estimation from genotype microarray data only reflects the mLOY degree of subjects at the moment of DNA sampling. Therefore, mLOY phenotype associations with AD can be severely age-confounded in the context of genome-wide association studies. Here, we applied Mendelian randomisation to construct an age-independent mLOY polygenic risk score (mloy-PRS) using 114 autosomal variants. The mloy-PRS instrument was associated with an 80% increase in mLOY risk per standard deviation unit (p = 4.22 × 10−20) and was orthogonal with age. We found that a higher genetic risk for mLOY was associated with faster progression to AD in men with mild cognitive impairment (hazard ratio (HR) = 1.23, p = 0.01). Importantly, mloy-PRS had no effect on AD conversion or risk in the female group, suggesting that these associations are caused by the inherent loss of the Y chromosome. Additionally, the blood mLOY phenotype in men was associated with increased cerebrospinal fluid levels of total tau and phosphorylated tau181 in subjects with mild cognitive impairment and dementia. Our results strongly suggest that mLOY is involved in AD pathogenesis., P.G.-G. (Pablo García-González) is supported by CIBERNED employment plan CNV-304-PRF-866. CIBERNED is integrated into ISCIII (Instituto de Salud Carlos III). I.d.R is supported by a national grant from the Instituto de Salud Carlos III FI20/00215. A.C. (Amanda Cano) acknowledges the support of the Spanish Ministry of Science, Innovation, and Universities under the grant Juan de la Cierva (FJC2018-036012-I). M.B. (Mercé Boada) and A.R. (Agustín Ruiz) are also supported by national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240, and PI19/01301. The Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria “La Caixa”, Fundació ACE, and CIBERNED. Acción Estratégica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII (Instituto de Salud Carlos III)—Subdirección General de Evaluación—and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de hacer Europa”). Genotyping of the ACE MCI-EADB samples was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW project number 733051061). This work was supported by a grant (European Alzheimer DNA BioBank, EADB) from the EU Joint Program—Neurodegenerative Disease Research (JPND)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Connecting genomic and proteomic signatures of amyloid burden in the brain

  • Puerta, Raquel
  • de Rojas, Itziar
  • García-González, Pablo
  • Olivé-Roig, Claudia
  • Sotolongo-Grau, Oscar
  • García-Sánchez, Ainhoa
  • García-Gutiérrez, Fernando
  • Montrreal, Laura
  • Tartari, Juan Pablo
  • Sanabria, Ángela
  • Pytel, Vanesa
  • Lage, Carmen
  • Quintela, Ines
  • Aguilera, Nuria
  • Rodríguez-Rodríguez, Eloy
  • Alarcón-Martín, Emilio
  • Orellana, Adelina
  • Pastor, Pau
  • Pérez-Tur, Jordi
  • Pinol-Ripoll, Gerard
  • López de Munain, Adolfo
  • García-Alberca, José María
  • Royo, José Luis
  • Bullido, María Jesús
  • Álvarez, Victoria
  • Real, Luis Miguel
  • Corbatón Anchuelo, Arturo
  • Gómez-Garre, Dulcenombre
  • Martínez Larrad, María Teresa
  • Franco-Macias, Emilio
  • Mir, Pablo
  • Medina, Miguel
  • Sánchez-Valle, Raquel
  • Icardo, Oriol
  • Dols-Sáez, María Eugenia
  • Carracedo, Ángel
  • Tárraga, Lluís
  • Alegret, Montse
  • Valero, Sergi
  • Marquie, Marta
  • Boada, Mercè
  • Juan, Pascual
  • Sánchez Cavazos, José Enrique
  • Cabrera, Alfredo
  • Cano, Amanda
  • Ruiz, Agustín
preprint 42 páginas, 6 figuras, 2 tablas, Background: Alzheimer's disease (AD) has a high heritable component characteristic of complex diseases, yet many of the genetic risk factors remain unknown. We combined genome-wide association studies (GWAS) on amyloid endophenotypes measured in cerebrospinal fluid (CSF) and positron emission tomography (PET) as surrogates of amyloid pathology, which may be helpful to understand the underlying biology of the disease. Methods: We performed a meta-analysis of GWAS of CSF Aβ42 and PET measures combining six independent cohorts (n=2,076). Due to the opposite effect direction of Aβ phenotypes in CSF and PET measures, only genetic signals in the opposite direction were considered for analysis (n=376,599). Polygenic risk scores (PRS) were calculated and evaluated for AD status and amyloid endophenotypes. We then searched the CSF proteome signature of brain amyloidosis using SOMAscan proteomic data (Ace cohort, n=1,008) and connected it with GWAS results of loci modulating amyloidosis. Finally, we compared our results with a large meta-analysis using publicly available datasets in CSF (n=13,409) and PET (n=13,116). This combined approach enabled the identification of overlapping genes and proteins associated with amyloid burden and the assessment of their biological significance using enrichment analyses. Results: After filtering the meta-GWAS, we observed genome-wide significance in the rs429358-APOE locus and nine suggestive hits were annotated. We replicated the APOE loci using the large CSF-PET meta-GWAS and identified multiple AD-associated genes as well as the novel GADL1 locus. Additionally, we found a significant association between the AD PRS and amyloid levels, whereas no significant association was found between any Aβ PRS with AD risk. CSF SOMAscan analysis identified 1,387 FDR-significant proteins associated with CSF Aβ42 levels. The overlap among GWAS loci and proteins associated with amyloid burden was very poor (n=35). The enrichment analysis of overlapping hits strongly suggested several signalling pathways connecting amyloidosis with the anchored component of the plasma membrane, synapse physiology and mental disorders that were replicated in the large CSF-PET meta-analysis. Conclusions: The strategy of combining CSF and PET amyloid endophenotypes GWAS with CSF proteome analyses might be effective for identifying signals associated with the AD pathological process and elucidate causative molecular mechanisms behind the amyloid mobilization in AD., The Genome Research @ Ace Alzheimer Center Barcelona project (GR@ACE) is supported by Grifols SA, Fundación bancaria 'La Caixa', Ace Alzheimer Center Barcelona and CIBERNED. Ace Alzheimer Center Barcelona is one of the participating centers of the Dementia Genetics Spanish Consortium (DEGESCO). The FACEHBI study is supported by funds from Ace Alzheimer Center Barcelona, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne and IrsiCaixa. Authors acknowledge the support of the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grants PID2021-122473OA-I00, PID2021-123462OB-I00 and PID2019-106625RB-I00. ISCIII, Acción Estratégica en Salud, integrated in the Spanish National R+D+I Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER 'Una manera de hacer Europa') grants PI13/02434, PI16/01861, PI17/01474, PI19/00335, PI19/01240, PI19/01301, PI22/01403, PI22/00258 and the ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). The support of CIBERNED (ISCIII) under the grants CB06/05/2004 and CB18/05/00010. The support from the ADAPTED and MOPEAD projects, European Union/EFPIA Innovative Medicines Initiative Joint (grant numbers 115975 and 115985, respectively); from PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant AC19/00097; from HARPONE project, Agency for Innovation and Entrepreneurship (VLAIO) grant PR067/21 and Janssen. DESCARTES project is funded by German Research Foundation (DFG). Additionally, IdR is supported by the Instituto de Salud Carlos III (ISCIII) under grant FI20/00215. PGG is supported by CIBERNED employment plan (CNV-304-PRF-866). ACF received support from the ISCIII under the grant Sara Borrell (CD22/00125). JEC received support from National Institute of Health award P30AG066546., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Associations of plasma SMOC1 and soluble IL6RA levels with the progression from mild cognitive impairment to dementia

  • Morató, Xavier
  • Puerta, Raquel
  • Cano, Amanda
  • Orellana, Adelina
  • de Rojas, Itziar
  • Capdevila, María
  • Montrreal, Laura
  • Rosende-Roca, Maitée
  • García-González, Pablo
  • Olivé, Claudia
  • García-Gutiérrez, Fernando
  • Blázquez, Josep
  • Miguel, Andrea
  • Núñez-Llaves, Raúl
  • Pytel, Vanesa
  • Alegret, Montserrat
  • Fernández, María Victoria
  • Marquié, Marta
  • Valero, Sergi
  • Cavazos, Jose Enrique
  • Mañes, Santos
  • Boada, Mercè
  • Cabrera-Socorro, Alfredo
  • Ruiz, Agustín
Despite the central role attributed to neuroinflammation in the etiology and pathobiology of Alzheimer's disease (AD), the direct link between levels of inflammatory mediators in blood and cerebrospinal fluid (CSF) compartments, as well as their potential implications for AD diagnosis and progression, remains inconclusive. Moreover, there is debate on whether inflammation has a protective or detrimental effect on disease onset and progression. Indeed, distinct immunological mechanisms may govern protective and damaging effects at early and late stages, respectively. This study aims to (i) identify inflammatory mediators demonstrating robust correlations between peripheral and central nervous system (CNS) compartments by means of plasma and CSF analysis, respectively, and (ii) assess their potential significance in the context of AD and disease progression from mild cognitive impairment (MCI) to dementia. To achieve this, we have examined the inflammatory profile of a well-defined subcohort comprising 485 individuals from the Ace Alzheimer Center Barcelona (ACE). Employing a hierarchical clustering approach, we thoroughly evaluated the intercompartmental correlations of 63 distinct inflammation mediators, quantified in paired CSF and plasma samples, using advanced SOMAscan technology. Of the array of mediators investigated, only six mediators (CRP, IL1RAP, ILRL1, IL6RA, PDGFRB, and YKL-40) exhibited robust correlations between the central and peripheral compartments (proximity scores <400). To strengthen the validity of our findings, these identified mediators were subsequently validated in a second subcohort of individuals from ACE (n = 873). The observed plasma correlations across the entire cohort consistently have a Spearman rho value above 0.51 (n = 1,360, p < 1.77E-93). Of the high CSF-plasma correlated proteins, only soluble IL6RA (sIL6RA) displayed a statistically significant association with the conversion from MCI to dementia. This association remained robust even after applying a stringent Bonferroni correction (Cox proportional hazard ratio [HR] = 1.936 per standard deviation; p = 0.0018). This association retained its significance when accounting for various factors, including CSF amyloid (Aβ42) and Thr181-phosphorylated tau (p-tau) levels, age, sex, baseline Mini-Mental State Examination (MMSE) score, and potential sampling biases identified through principal component analysis (PCA) modeling. Furthermore, our study confirmed the association of both plasma and CSF levels of SPARC-related modular calcium-binding protein 1 (SMOC1) with amyloid and tau accumulation, indicating their role as early surrogate biomarkers for AD pathology. Despite the lack of a statistically significant correlation between SMOC1 levels in CSF and plasma, both acted as independent biomarkers of disease progression (HR > 1.3, p < 0.002). In conclusion, our study unveils that sIL6RA and SMOC1 are associated with MCI progression. The absence of correlations among inflammatory mediators between the central and peripheral compartments appears to be a common pattern, with only a few intriguing exceptions., A. Ruiz received support from the HARPONE project, Agency for Innovation and Entrepreneurship (VLAIO) grant Nº PR067/21 and Jansen; from the PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant Nº AC19/00097; from the ADAPTED project, EU/EFPIA Innovative Medicines Initiative Joint Undertaking grant Nº 115975; from the DESCARTES project, German Research Foundation (DFG); and from Fundación Bancaria“La Caixa”, Fundación Echevarne and Grifols S.A. (GR@ACE project). Research funding support for the analyses was granted to the Ace Alzheimer Center Barcelona (X. Morató and M. Boada) by Novo Nordisk. S. Manes received support from the Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033) (grant PID2020-116303RB-I00). The authors acknowledge the support of the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00. Support was also given by Acción Estratégica en Salud, integrated into the Spanish National R +D +I Plan and financed by ISCIII Subdirección General de Evaluaci´ on and Fondo Europeo de Desarrollo Regional (FEDER“Una manera de hacer Europa") grants PI17/01474, PI19/00335, PI22/01403, and PI22/00258 and ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). The support of CIBERNED (ISCIII) under grants CB06/05/ 2004 and CB18/05/00010 is also acknowledged. A. Cano received support from the Instituto de Salud Carlos III (ISCIII) under the grant Sara Borrell (CD22/00125) and from Fundación ADEY (under the program“Proyectos de Investigacioón en Salud 2023”). I. de Rojas was supported by ISCIII under grant FI20/00215. P. García-Gonz´ alez was supported by the CIBERNED employment plan (CNV-304-PRF-866). S. Valero received support from the TARTAGLIA project, the program of the Spanish Ministry of Science and Innovation R&D Missions in Artificial Intelligence, the Spain Digital 2025 Agenda, and the National Artificial Intelligence Strategy, financed by the European Union through Next Generation EU funds, under grant Nº MIA.2021.M02.0005., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Linking genomic and proteomic signatures to brain amyloid burden: insights from GR@ACE/DEGESCO

  • Puerta, Raquel
  • Pérez-Tur, Jordi
  • Bullido, María Jesús
  • Real, Luis Miguel
  • Mir, Pablo
  • Ruiz, Agustín
  • Alzheimer’s Disease Neuroimaging Initiative
27 páginas, 7 figuras, 3 tablas, Alzheimer's disease (AD) is a complex disease with a strong genetic component, yet many genetic risk factors remain unknown. We combined genome-wide association studies (GWAS) on amyloid endophenotypes measured in cerebrospinal fluid (CSF) and positron emission tomography (PET) as surrogates of amyloid pathology, which may provide insights into the underlying biology of the disease. We performed a meta-GWAS of CSF Aβ42 and PET measures combining six independent cohorts (n = 2,076). Given the opposite beta direction of Aβ phenotypes in CSF and PET measures, only genetic signals showing opposite directions were considered for analysis (n = 376,599). We explored the amyloidosis signature in the CSF proteome using SOMAscan proteomics (ACE cohort, n = 1,008), connected it with GWAS loci modulating amyloidosis and performed an enrichment analysis of overlapping hits. Finally, we compared our results with a large meta-analysis using publicly available datasets in CSF (n = 13,409) and PET (n = 13,116). After filtering the meta-GWAS, we observed genome-wide significance in the rs429358-APOE locus and annotated nine suggestive hits. We replicated the APOE loci using the large CSF-PET meta-GWAS, identifying multiple AD-associated genes including the novel GADL1 locus. Additionally, we found 1,387 FDR-significant SOMAscan proteins associated with CSF Aβ42 levels. The overlap among GWAS loci and proteins associated with amyloid burden was minimal (n = 35). The enrichment analysis revealed mechanisms connecting amyloidosis with the plasma membrane's anchored component, synapse physiology and mental disorders that were replicated in the large CSF-PET meta-analysis. Combining CSF and PET amyloid GWAS with CSF proteome analyses may effectively elucidate causative molecular mechanisms behind amyloid mobilization and AD physiopathology., The Genome Research @ Ace Alzheimer Center Barcelona project (GR@ACE) is supported by Grifols SA, Fundación bancaria ‘La Caixa’, Ace Alzheimer Center Barcelona and CIBERNED. Ace Alzheimer Center Barcelona is one of the participating centers of the Dementia Genetics Spanish Consortium (DEGESCO). The FACEHBI study is supported by funds from Ace Alzheimer Center Barcelona, Grifols, Life Molecular Imaging, Araclon Biotech, Alkahest, Laboratorio de análisis Echevarne and IrsiCaixa. Authors acknowledge the support of the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grants PID2021-122473OA-I00, PID2021-123462OB-I00 and PID2019-106625RB-I00. ISCIII, Acción Estratégica en Salud, integrated in the Spanish National R + D + I Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER “Una manera de hacer Europa") grants PI13/02434, PI16/01861, PI17/01474, PI19/00335, PI19/01240, PI19/01301, PI22/01403, PI22/00258 and the ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). The support of CIBERNED (ISCIII) under the grants CB06/05/2004 and CB18/05/00010. The support from the ADAPTED and MOPEAD projects, European Union/EFPIA Innovative Medicines Initiative Joint (grant numbers 115975 and 115985, respectively); from PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant Nº AC19/00097; from HARPONE project, Agency for Innovation and Entrepreneurship (VLAIO) grant Nº PR067/21 and Janssen. DESCARTES project is funded by German Research Foundation (DFG). Additionally, AR is also supported by STAR Award. University of Texas System. Tx, United States, The South Texas ADRC. National Institute of Aging. National Institutes of Heath. USA. (P30AG066546) and the Keith M. Orme and Pat Vigeon Orme Endowed Chair in Alzheimer’s and Neurodegenerative Diseases. IdR is supported by the Instituto de Salud Carlos III (ISCIII) under grant FI20/00215. PGG is supported by CIBERNED employment plan (CNV-304-PRF-866). ACF received support from the ISCIII under the grant Sara Borrell (CD22/00125). JEC received support from National Institute of Health award P30AG066546., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Spanish-Portuguese GWAS of progressive supranuclear palsy reveals a novel risk locus in NFASC

  • García-González, Pablo
  • Díaz Belloso, Rafael
  • Munoz-Delgado, Laura
  • Buiza Rueda, Dolores
  • Gómez-Garre, Pilar
  • Pérez-Tur, Jordi
  • Real, Luis M.
  • Bullido, María Jesús
  • Ruiz, Agustín
18 páginas, 2 figuras, Progressive supranuclear palsy (PSP) is a rare 4-repeat tauopathy that causes behavioural, movement and cognitive abnormalities. We genotyped all available clinical and histopathological PSP cases in Spain and Portugal (N = 522), and conducted the largest PSP GWAS of the Iberian population to date. Genetic burden analysis revealed reduced diagnostic specificity in clinically diagnosed atypical PSP cases-when applying the 2017 MDS criteria-compared to Richardson's syndrome cases. We independently replicated eight PSP risk variants in seven known loci (MAPT, MOBP, EIF2AK3, STX6, SLCO1A2, DUSP10 and APOE), and identified a novel locus in NFASC/CNTN2 (rs12744678 C: OR[95%CI] = 0.83[0.78-0.89]; p = 4.15·10-08) after meta-analysis with a newly available Dutch cohort and publicly available summary statistics (3,099 PSP; 11,482 controls). Enrichment analysis and protein expression profiling highlighted oligodendrocyte function and myelination as likely contributors to PSP pathogenesis. Our findings broaden the genetic landscape of PSP and suggest potential therapeutic avenues focused on modulating neuron-oligodendrocyte interactions., This work was funded by CIBERNED (Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas) 10th internal call for cooperative projects (Register number: 2019/09). Agustín Ruiz, Pascual Sanchez-Juan, Alberto Rábano, and Maria J. Bullido received funding from this convocatory. Pablo García-González received support by CIBERNED employment plan CNV-304-PRF-866. CIBERNED is integrated into ISCIII (Instituto de Salud Carlos III). Mercé Boada, Marta Marquié and Agustín Ruiz are also supported by national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240, PI19/01301, PI19/00335 and PI22/011403, and CIBERNED grant 2019/08. The Genome Research @ Fundació ACE project (GR@ACE) is supported by Grifols SA, Fundación bancaria “La Caixa”, Fundació ACE, and CIBERNED. Acción Estratégica en Salud is integrated into the Spanish National R  +  D  +  I Plan and funded by ISCIII—Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de hacer Europa”). Agustín Ruiz is supported by ISCIII national grant PMP22/00022, funded by the European Union (NextGenerationEU). He is also supported by the STAR Award. University of Texas System. Tx, United States, The South Texas ADRC. National Institute of Aging. National Institutes of Health. USA. (P30AG066546), the Keith M. Orme and Pat Vigeon Orme Endowed Chair in Alzheimer’s and Neurodegenerative Diseases (2024-2025) and Patricia Ruth Frederick Distinguished Chair for Precision Therapeutics in Alzheimer’s and Neurodegenerative Diseases (2025-2028). The genotyping service to generate GR@ACE and PSP/DEGESCO GWAS data was carried out at CEGEN-PRB3-ISCIII; it is supported by grant PT17/0019, of the PE I + D + i 2013-2016, funded by ISCIII and ERDF”. Itziar de Rojas received support by a national grant from ISCIII FI20/00215. Amanda Cano acknowledges the support of the Spanish Ministry of Science, Innovation and Universities under the grant Juan de la Cierva (FJC2018-036012-I), the support of ISCIII under the grant Sara Borrell (CD22/00125), Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grant PID2021-122473OA-I00, and Fundación ADEY under the program “Proyectos de Investigación en Salud 2023”. Fondo de Investigacion en Salud (Instituto Carlos III) (PI17/00096) in the frame of the European Regional Development Fund (ERDF) and to Fundacio ́ la Marato ́ de TV3 (PI043296 and 202009-10). This work was supported by the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (PI14/01823, PI16/01575, PI18/01898, PI19/01576, PI21/01875), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685, PY20_00896), and the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019). Pilar Gómez-Garre was supported by the “Nicolás Monardes” program (C-0048-2017) from Andalusian Regional Ministry of Health. Laura Muñoz-Delgado was supported by the “Río Hortega” program [CM21/00051] from the Instituto de Salud Carlos III (ISCIII-FEDER). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Sven J. van der Lee was funded for this study by NWO (#733050512, PROMO-GENODE: a PROspective study of MOnoGEnic causes Of Dementia) a substantial donation by Edwin Bouw Fonds and Dioraphte. SvdL further received funding for the GeneMINDS consortium, which is powered by Health~Holland, Top Sector Life Sciences & Health. Sven J. van der Lee is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbisfonds. ABOARD also receives funding from de Hersenstichting, Edwin Bouw Fonds and Gieskes-Strijbisfonds. Array genotyping was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW projectnumber 733051061). This work has been supported by the Queen Sofia Foundation. Pascual Sánchez-Juan is supported by grants from ISCIII (PMP22/00022 and PI20/01011) and TED2021-131676B-100. Luis Miguel Real received support from “The absence of seroconversion after exposition to hepatitis C virus is not related to KIR-HLA genotype combinations” (GEHEP-012 study). Consejería de Salud de la Junta de Andalucía (grant number PI-0001/2017) and CIBERINFEC -Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas- Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación y Unión Europea (Spain) (NextGeneration EU) (grant number CB21/13/00118). Jose Luis Royo received support from Project 23.04.2021 from Santángela Foundation (Sevilla, Spain)., Peer reviewed
Repositorio Institucional de la Universidad de Burgos (RIUBU)
Publicación Artículo científico (JournalArticle)

EVIDENT smartphone app, a new method for the dietary record: comparison with a food frequency questionnaire

  • Recio Rodríguez, José I.
  • Rodríguez Martín, Carmela
  • González Sánchez, Jesús
  • Rodríguez Sánchez, Emiliano
  • Martín Borras, Carme
  • Martínez Vizcaino, Vicente
  • Arietaleanizbeaskoa, María Soledad
  • Magdalena González, Olga
  • Fernández Alonso, Carmen
  • Maderuelo Fernández, José A.
  • Gómez Marcos, Manuel A.
  • García Ortiz, Luis
  • On Behalf of the EVIDENT Investigators
Background: More alternatives are needed for recording people’s normal diet in different populations, especially adults or the elderly, as part of the investigation into the effects of nutrition on health. Objective: The aim of this study was to compare the estimated values of energy intake, macro- and micronutrient, and alcohol consumption gathered using the EVIDENT II smartphone app against the data estimated with a food frequency questionnaire (FFQ) in an adult population aged 18 to 70 years. Methods: We included 362 individuals (mean age 52 years, SD 12; 214/362, 59.1% women) who were part of the EVIDENT II study. The participants registered their food intake using the EVIDENT app during a period of 3 months and through an FFQ. Both methods estimate the average nutritional composition, including energy intake, macro- and micronutrients, and alcohol. Through the app, the values of the first week of food recording, the first month, and the entire 3-month period were estimated. The FFQ gathers data regarding the food intake of the year before the moment of interview. Results: The intraclass correlation for the estimation of energy intake with the FFQ and the app shows significant results, with the highest values returned when analyzing the app’s data for the full 3-month period (.304, 95% CI 0.144-0.434; P<.001). For this period, the correlation coefficient for energy intake is .233 (P<.001). The highest value corresponds to alcohol consumption and the lowest to the intake of polyunsaturated fatty acids (r=.676 and r=.155; P<.001), respectively. The estimation of daily intake of energy, macronutrients, and alcohol presents higher values in the FFQ compared with the EVIDENT app data. Considering the values recorded during the 3-month period, the FFQ for energy intake estimation (Kcal) was higher than that of the app (a difference of 408.7, 95% CI 322.7-494.8; P<.001). The same is true for the other macronutrients, with the exception g/day of saturated fatty acids (.4, 95% CI −1.2 to 2.0; P=.62). Conclusions: The EVIDENT app is significantly correlated to FFQ in the estimation of energy intake, macro- and micronutrients, and alcohol consumption. This correlation increases with longer app recording periods. The EVIDENT app can be a good alternative for recording food intake in the context of longitudinal or intervention studies. Trial Registration: ClinicalTrials.gov NCT02016014; http://clinicaltrials.gov/ct2/show/NCT02016014 (Archived by WebCite at http://www.webcitation.org/760i8EL8Q)., Spanish Ministry of Science and Innovation and Carlos III Health Institute/European Regional Development Fund (FIS: PI13/00618, PI13/01526, PI13/00058, PI13/01635, PI13/02528, PI12/01474; RETICS: RD12/0005, RD16/0007), Regional Health Management of Castilla and León (GRS 1191/B/15, GRS 909/B/14, GRS 770/B/13), and the Infosalud Foundation
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Short-term effectiveness of a mobile phone app for increasing physical activity and adherence to the mediterranean diet in primary care: A randomized controlled trial (EVIDENT II study)

  • Recio-Rodriguez, J.
  • Agudo-Conde, C.
  • Martin-Cantera, C.
  • González-Viejo, M.
  • Fernandez-Alonso, M.
  • Arietaleanizbeaskoa, M.S.
  • Schmolling-Guinovart, Y.
  • Maderuelo-Fernandez, J.
  • Rodriguez-Sanchez, E.
  • Gomez-Marcos, M.
  • Garcia-Ortiz, L.
Background: The use of mobile phone apps for improving lifestyles has become generalized in the population, although little is still known about their effectiveness in improving health. Objective: We evaluate the effect of adding an app to standard counseling on increased physical activity (PA) and adherence to the Mediterranean diet, 3 months after implementation. Methods: A randomized, multicenter clinical trial was carried out. A total of 833 participants were recruited in six primary care centers in Spain through random sampling: 415 in the app+counseling group and 418 in the counseling only group. Counseling on PA and the Mediterranean diet was given to both groups. The app+counseling participants additionally received training in the use of an app designed to promote PA and the Mediterranean diet over a 3-month period. PA was measured with the 7-day Physical Activity Recall (PAR) questionnaire and an accelerometer; adherence to the Mediterranean diet was assessed using the Mediterranean Diet Adherence Screener questionnaire. Results: Participants were predominantly female in both the app+counseling (249/415, 60.0%) and counseling only (268/418, 64.1%) groups, with a mean age of 51.4 (SD 12.1) and 52.3 (SD 12.0) years, respectively. Leisure-time moderate-to-vigorous physical activity (MVPA) by 7-day PAR increased in the app+counseling (mean 29, 95% CI 5-53 min/week; P=.02) but not in the counseling only group (mean 17.4, 95% CI ''18 to 53 min/week; P=.38). No differences in increase of activity were found between the two groups. The accelerometer recorded a decrease in PA after 3 months in both groups: MVPA mean ''55.3 (95% CI ''75.8 to ''34.9) min/week in app+counseling group and mean ''30.1 (95% CI ''51.8 to ''8.4) min/week in counseling only group. Adherence to the Mediterranean diet increased in both groups (8.4% in app+counseling and 10.4% in counseling only group), with an increase in score of 0.42 and 0.53 points, respectively (P<.001), but no difference between groups (P=.86). Conclusions: Leisure-time MVPA increased more in the app+counseling than counseling only group, although no difference was found when comparing the increase between the two groups. Counseling accompanied by printed materials appears to be effective in improving adherence to the Mediterranean diet, although the app does not increase adherence.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

The effectiveness of a smartphone application on modifying the intakes of macro and micronutrients in primary care: A randomized controlled trial. the EVIDENT II study

  • Recio-Rodriguez, J.I.
  • Conde, C.A.
  • Calvo-Aponte, M.J.
  • Gonzalez-Viejo, N.
  • Fernandez-Alonso, C.
  • Mendizabal-Gallastegui, N.
  • Rodriguez-Martin, B.
  • Maderuelo-Fernandez, J.A.
  • Rodriguez-Sanchez, E.
  • Gomez-Marcos, M.A.
  • Garcia-Ortiz, L.
  • EVIDENT, Investigators
Background: This study evaluates the effectiveness of adding a diet smartphone application to standard counseling to modify dietary composition over the long term (12 months). Methods: A randomized, controlled, multicenter clinical trial was conducted involving the participation of 833 subjects from primary care clinics (415 to the intervention (counseling + application) group (IG) and 418 to the control (counseling) group (CG)). Both groups were counseled about a healthy diet and physical activity. For the 3-month intervention period, the IG was also trained to use a diet smartphone application that involved dietary self-monitoring and tailored feedback. Nutritional composition was estimated using a self-reported food frequency questionnaire. Results: An analysis of repeated measures revealed an interaction between the group and the percentages of carbohydrates (p = 0.031), fats (p = 0.015) and saturated fats (p = 0.035) consumed. Both groups decreased their energy intake (Kcal) at 12 months (IG: -114 (95% CI: -191 to -36); CG: -108 (95% CI: -184 to -31)). The IG reported a higher percentage intake of carbohydrates (1.1%; 95% CI: 0.1 to 2.0), and lower percentage intakes of fats (-1.0%; 95% CI: -1.9 to -0.1) and saturated fats (-0.4%; 95%CI: -0.8 to -0.1) when compared to the CG. Conclusions: Better results were achieved in terms of modifying usual diet composition from counseling and the diet smartphone application compared to counseling alone. This was evaluated by a self-reported questionnaire, which indicated an increased percentage intake of carbohydrates, and decreased percentage intakes of fats and saturated fats.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

The relationship of the atlantic diet with cardiovascular risk factors and markers of arterial stiffness in adults without cardiovascular disease

  • Rodríguez-Martín, C.
  • Garcia-Ortiz, L.
  • Rodriguez-Sanchez, E.
  • Martin-Cantera, C.
  • Soriano-Cano, A.
  • Arietaleanizbeaskoa, M.S.
  • Magdalena-Belio, J.F.
  • Menendez-Suarez, M.
  • Maderuelo-Fernandez, J.A.
  • Lugones-Sanchez, C.
  • Gómez-Marcos, M.A.
  • Recio-Rodríguez, J.I.
  • EVIDENT, Investigators, Group
Background: Studying the adherence of the population to the Atlantic Diet (AD) could be simplified by an easy and quickly applied dietary index. The aim of this study is to analyse the relationship of an index measuring compliance with recommendations regarding the Atlantic diet and physical activity with cardiovascular disease risk factors, cardiovascular risk factors, obesity indexes and arterial stiffness markers. Methods: We included 791 individuals from the EVIDENT study (lifestyles and arterial ageing), (52.3 ± 12 years, 61.7% women) without cardiovascular disease. Compliance with recommendations on AD was collected through the responses to a food frequency questionnaire, while physical activity was measured by accelerometer. The number of recommendations being met was estimated using a global scale between 0 and 14 points (a higher score representing greater adherence). Blood pressure, plasma lipid and glucose values and obesity rates were measured. Cardiovascular risk was estimated with the Framingham equation. Results: In the overall sample, 184 individuals (23.3%) scored between 0–3 on the 14-point index we created, 308 (38.9%) between 4 and 5 points, and 299 (37.8%) 6 or more points. The results of multivariate analysis yield a common tendency in which the group with an adherence score of at least 6 points shows lower figures for total cholesterol (p = 0.007) and triglycerides (p = 0.002). Similarly, overall cardiovascular risk in this group is the lowest (p < 0.001), as is pulse wave velocity (p = 0.050) and the mean values of the obesity indexes studied (p < 0.05 in all cases). Conclusion: The rate of compliance with the Atlantic diet and physical activity shows that greater adherence to these recommendations is linked to lower cardiovascular risk, lower total cholesterol and triglycerides, lower rates of obesity and lower pulse wave velocity values.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Short-Term Effectiveness of a Mobile Phone App for Increasing Physical Activity and Adherence to the Mediterranean Diet in Primary Care, A Randomized Controlled Trial (EVIDENT II Study)

  • Recio Rodríguez, José I.|||0000-0002-3772-8746
  • Agudo-Conde, Cristina|||0000-0002-9381-4024
  • Martín-Cantera, Carlos|||0000-0003-0656-8126
  • González, Mª Natividad|||0000-0003-2299-2410
  • Fernandez-Alonso, Mª Del Carmen|||0000-0003-3541-6359
  • Arietaleanizbeaskoa, Maria Soledad|||0000-0001-8747-6789
  • Schmolling-Guinovart, Yolanda|||0000-0001-7838-9931
  • Maderuelo-Fernandez, Jose-Angel|||0000-0001-7544-8684
  • Rodríguez Sánchez, Emiliano|||0000-0003-3667-7155
  • Gomez-Marcos, Manuel A.|||0000-0003-0133-6123
  • Garcia-Ortiz, Luis|||0000-0001-6555-8302
The use of mobile phone apps for improving lifestyles has become generalized in the population, although little is still known about their effectiveness in improving health. We evaluate the effect of adding an app to standard counseling on increased physical activity (PA) and adherence to the Mediterranean diet, 3 months after implementation. A randomized, multicenter clinical trial was carried out. A total of 833 participants were recruited in six primary care centers in Spain through random sampling: 415 in the app+counseling group and 418 in the counseling only group. Counseling on PA and the Mediterranean diet was given to both groups. The app+counseling participants additionally received training in the use of an app designed to promote PA and the Mediterranean diet over a 3-month period. PA was measured with the 7-day Physical Activity Recall (PAR) questionnaire and an accelerometer; adherence to the Mediterranean diet was assessed using the Mediterranean Diet Adherence Screener questionnaire. Participants were predominantly female in both the app+counseling (249/415, 60.0%) and counseling only (268/418, 64.1%) groups, with a mean age of 51.4 (SD 12.1) and 52.3 (SD 12.0) years, respectively. Leisure-time moderate-to-vigorous physical activity (MVPA) by 7-day PAR increased in the app+counseling (mean 29, 95% CI 5-53 min/week; P =.02) but not in the counseling only group (mean 17.4, 95% CI -18 to 53 min/week; P =.38). No differences in increase of activity were found between the two groups. The accelerometer recorded a decrease in PA after 3 months in both groups: MVPA mean -55.3 (95% CI -75.8 to -34.9) min/week in app+counseling group and mean -30.1 (95% CI -51.8 to -8.4) min/week in counseling only group. Adherence to the Mediterranean diet increased in both groups (8.4% in app+counseling and 10.4% in counseling only group), with an increase in score of 0.42 and 0.53 points, respectively (P <.001), but no difference between groups (P =.86). Leisure-time MVPA increased more in the app+counseling than counseling only group, although no difference was found when comparing the increase between the two groups. Counseling accompanied by printed materials appears to be effective in improving adherence to the Mediterranean diet, although the app does not increase adherence. Clinicaltrials.gov NCT02016014; https://clinicaltrials.gov/ct2/show/NCT02016014 (Archived by WebCite at http://www.webcitation.org/6mnopADbf).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks, The GR@ACE project

  • Moreno-Grau, Sonia
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Hernández, Isabel|||0000-0001-8119-393X
  • Quintela, Inés|||0000-0002-0239-7975
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Hernández-Olasagarre, Begoña
  • Madrid, Laura|||0000-0001-5851-3341
  • González-Perez, Antonio
  • Maroñas, Olalla
  • Rosende-Roca, Maitée|||0000-0003-1778-8175
  • Mauleón, Ana|||0000-0002-4218-2127
  • Vargas, Liliana|||0000-0001-5685-5903
  • Lafuente, Asunción
  • Abdelnour, Carla|||0000-0002-7636-9758
  • Rodríguez-Gómez, Octavio
  • Gil-Navarro, Silvia|||0000-0001-9921-9042
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Espinosa, Ana|||0000-0001-7399-3267
  • Ortega Linares, Gemma|||0000-0002-7479-4072
  • Sanabria, Ángela|||0000-0002-7501-9895
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Cañabate, Pilar
  • Moreno, Mariola
  • Preckler, Silvia
  • Ruiz, Susana
  • Aguilera, Núria
  • Pineda, Juan Antonio
  • Macías, Juan|||0000-0002-4778-790X
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Benaque, Alba
  • Boada, Mercè|||0000-0003-2617-3009
  • Buendía, Mar
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Corbatón-Anchuelo, Arturo
  • Diego, S.
  • Gailhajenet, A.
  • García González, P.
  • Guitart, Maria|||0000-0003-2957-7404
  • Ibarria, Marta
  • Macias, J.
  • Martín, E.
  • Martínez, M. T.
  • Marquié, Marta|||0000-0002-0660-0950
  • Monté-Rubio, Gemma C.|||0000-0002-3532-2224
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Pancho, A.
  • Pelejà, E.
  • Real, L. M.
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Ruiz-Janer, Sabina|||0000-0002-8073-9504
  • Sáez, María Eugenia|||0000-0001-9299-2534
  • Serrano-Rios, M.
  • Tárraga, L.
  • Valero, S.
  • Adarmes-Gómez, A.D.|||0000-0002-1337-9289
  • Álvarez, I.
  • Alvarez, Victoria|||0000-0002-1916-2523
  • Amer Ferrer, Guillermo
  • Antequera, M.
  • Antúnez, Carmen
  • Baquero, Miquel|||0000-0002-6861-1831
  • Bernal, M.
  • Blesa, Rafael|||0000-0003-4026-2884
  • Buiza-Rueda, Dolores|||0000-0002-3504-9299
  • Bullido, María J.|||0000-0002-6477-1117
  • Burguera, J. A.
  • Calero, Miguel|||0000-0001-5366-3324
  • Carrillo, F.
  • Carrión-Claro, M.
  • Casajeros, M. J.
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Cruz-Gamero, J. M.
  • Pancorbo, Marian M. de
  • del Ser, Teodoro|||0000-0001-9806-7083
  • Diez-Fairen, Monica|||0000-0003-1882-0309
  • Fortea, Juan|||0000-0002-1340-638X
  • Franco-Macías, Emilio|||0000-0003-4186-1037
  • Frank García, Ana
  • García-Alberca, J. M.
  • García-Madrona, Sebastián
  • García-Ribas, Guillermo
  • Gómez-Garre, Pilar|||0000-0002-0437-6182
  • Hevilla, S.
  • Jesús Maestre, Silvia|||0000-0002-1874-4628
  • Espinosa, Labrador
  • Lage, Carmen|||0000-0003-1703-121X
  • Legaz, A.
  • Lleó, Alberto|||0000-0002-2568-5478
  • López de Munáin, A.
  • López-García, S.
  • Macías-García, Daniel|||0000-0002-4822-1529
  • Manzanares, S.
  • Marín, M.
  • Marín Muñoz, Juan|||0000-0002-7512-6121
  • Marín, T.
  • Martín Montes, Angel|||0000-0002-1694-786X
  • Martínez, Benjamín|||0000-0001-9879-7748
  • Martínez, C.
  • Martínez, V.
  • Martínez-Lage Álvarez, P.
  • Medina, Miguel|||0000-0002-7016-5340
  • Mendioroz, Maite|||0000-0002-4179-5781
  • Menéndez González, Manuel
  • Mir, Pablo|||0000-0003-1656-302X
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Pastor, A. B.
  • Pástor, P.
  • Pérez-Tur, Jordi|||0000-0002-9111-1712
  • Periñán-Tocino, T.
  • Piñol-Ripoll, Gerard
  • Rábano, Alberto|||0000-0001-9320-6566
  • Real de Asua, D.
  • Rodrigo, S.
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Royo, J. L.
  • Sanchez del Valle Díaz, R.
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Sastre, I.
  • Vicente, M. P.
  • Vivancos, Liliana
  • Ávila, J.
Introduction: Large variability among Alzheimer's disease (AD) cases might impact genetic discoveries and complicate dissection of underlying biological pathways. Methods: Genome Research at Fundacio ACE (GR@ACE) is a genome-wide study of dementia and its clinical endophenotypes, defined based on AD's clinical certainty and vascular burden. We assessed the impact of known AD loci across endophenotypes to generate loci categories. We incorporated gene coexpression data and conducted pathway analysis per category. Finally, to evaluate the effect of heterogeneity in genetic studies, GR@ACE series were meta-analyzed with additional genome-wide association study data sets. Results: We classified known AD loci into three categories, which might reflect the disease clinical heterogeneity. Vascular processes were only detected as a causal mechanism in probable AD. The meta-analysis strategy revealed the ANKRD31-rs4704171 and NDUFAF6-rs10098778 and confirmed SCIMP-rs7225151 and CD33-rs3865444. Discussion: The regulation of vasculature is a prominent causal component of probable AD. GR@ACE meta-analysis revealed novel AD genetic signals, strongly driven by the presence of clinical heterogeneity in the AD series.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Long runs of homozygosity are associated with Alzheimer's disease

  • Moreno-Grau, Sonia
  • Fernández, Maria Victoria|||0000-0002-9669-5147
  • De Rojas, Itziar|||0000-0002-2148-381X
  • García-González, Pablo|||0000-0003-0125-5403
  • Hernández, Isabel|||0000-0001-8119-393X
  • Farias, Fabiana|||0000-0002-5215-7304
  • Budde, John P.|||0000-0001-7778-7276
  • Quintela, Inés|||0000-0002-0239-7975
  • Madrid, Laura|||0000-0001-5851-3341
  • González-Pérez, Antonio
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Maroñas, Olalla
  • Pineda, Juan Antonio
  • Macías, Juan|||0000-0002-4778-790X
  • Marquié, Marta|||0000-0002-0660-0950
  • Valero, Sergi|||0000-0002-6599-948X
  • Benaque, Alba
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Bullido, María J.|||0000-0002-6477-1117
  • García-Ribas, Guillermo
  • Pastor, Pau|||0000-0002-7493-8777
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Alvarez, Victoria|||0000-0002-1916-2523
  • Piñol-Ripoll, Gerard
  • García-Alberca, Jose María|||0000-0003-2951-6644
  • Royo, José Luis
  • Franco-Macías, Emilio|||0000-0003-4186-1037
  • Mir, Pablo|||0000-0003-1656-302X
  • Calero, Miguel|||0000-0001-5366-3324
  • Medina, Miguel|||0000-0002-7016-5340
  • Rábano, Alberto|||0000-0001-9320-6566
  • Ávila, Jesús
  • Antúnez, Carmen
  • Real, Luis M.|||0000-0003-4932-7429
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Sáez, María Eugenia|||0000-0001-9299-2534
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Boada, Mercè|||0000-0003-2617-3009
  • Cruchaga, Carlos|||0000-0002-0276-2899
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
Long runs of homozygosity (ROH) are contiguous stretches of homozygous genotypes, which are a footprint of inbreeding and recessive inheritance. The presence of recessive loci is suggested for Alzheimer's disease (AD); however, their search has been poorly assessed to date. To investigate homozygosity in AD, here we performed a fine-scale ROH analysis using 10 independent cohorts of European ancestry (11,919 AD cases and 9181 controls.) We detected an increase of homozygosity in AD cases compared to controls [ β (CI 95%) = 0.070 (0.037-0.104); P = 3.91 × 10 -5 ; β (CI95%) = 0.043 (0.009-0.076); P = 0.013]. ROHs increasing the risk of AD (OR.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

BIOFACE, A Prospective Study of Risk Factors, Cognition, and Biomarkers in a Cohort of Individuals with Early-Onset Mild Cognitive Impairment. Study Rationale and Research Protocols

  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Gil-Navarro, Silvia|||0000-0001-9921-9042
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Cano, Amanda|||0000-0001-9567-4283
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Espinosa, Ana|||0000-0001-7399-3267
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Valero, Sergi|||0000-0002-6599-948X
  • Martínez, Joan|||0000-0001-7962-709X
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Martín, Elvira
  • Vivas, Assumpta
  • Gómez Chiari, Marta|||0000-0001-6726-1721
  • Tejero, Miguel Ángel
  • Bernuz, Mireia|||0000-0002-2052-6902
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
Background: Mild cognitive impairment (MCI) due to Alzheimer's disease (AD) diagnosis is based on cerebrospinal fluid (CSF) or neuroimaging biomarkers. Currently, non-invasive and inexpensive blood-based biomarkers are being investigated, such as neuronal-derived plasma exosomes (NPEs). Neuroinflammation and early vascular changes have been described in AD pathogenesis and can be traced in plasma and NPEs. However, they have not been studied in early onset MCI (EOMCI). Objective: To describe the rationale, design, and baseline characteristics of the participants from the BIOFACE cohort, a two-year observational study on EOMCI conducted at Fundació ACE. The study goal is to characterize the different phenotypes from a clinical, neuropsychological, and biomarker point of view and to investigate the CSF and plasma proteomics as well as the role of NPEs as early biomarkers of AD. Methods: Participants underwent extended neurological and neuropsychological batteries, multimodal biomarkers including brain MRI, blood, saliva, CSF, anthropometric, and neuro-ophthalmological examinations. Results: Ninety-seven patients with EOMCI were recruited. 59.8%were women. Mean age at symptom onset was 57 years; mean MMSE was 28. First degree and presenile family history of dementia was present in 60.8%and 15.5%, respectively. Depressive and anxiety disorders along with vascular risk factors were the most frequent comorbidities. 29%of participants were APOE ɛ4 carriers, and 67%showed a CSF normal ATN profile. Conclusion: BIOFACE is a two-year study of clinical, cognition, and biomarkers that will shed light on the physiopathology and the potential utility of plasma and NPEs as non-invasive early diagnostic and prognostic biomarkers in people younger than 65 years.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Extracellular Vesicles as Drug Delivery Systems in Cancer

  • Hernández Oller, Laia|||0000-0003-4116-6595
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Andrade, Fernanda|||0000-0002-4947-2346
  • Rafael, Diana|||0000-0003-3180-3028
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Gener, Petra|||0000-0002-2250-570X
  • Schwartz, Simon|||0000-0001-8297-7971
Within tumors, Cancer Stem Cell (CSC) subpopulation has an important role in maintaining growth and dissemination while preserving high resistance against current treatments. It has been shown that, when CSCs are eliminated, the surrounding Differentiated Cancer Cells (DCCs) may reverse their phenotype and gain CSC-like features to preserve tumor progression and ensure tumor survival. This strongly suggests the existence of paracrine communication within tumor cells. It is evidenced that the molecular crosstalk is at least partly mediated by Extracellular Vesicles (EVs), which are cell-derived membranous nanoparticles that contain and transport complex molecules that can affect and modify the biological behavior of distal cells and their molecular background. This ability of directional transport of small molecules prospects EVs as natural Drug Delivery Systems (DDS). EVs present inherent homing abilities and are less immunogenic than synthetic nanoparticles, in general. Currently, strong efforts are focused into the development and improvement of EV-based DDS. Even though EV-DDS have already reached early phases in clinical trials, their clinical application is still far from commercialization since protocols for EVs loading, modification and isolation need to be standardized for large-scale production. Here, we summarized recent knowledge regarding the use of EVs as natural DDS against CSCs and cancer resistance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

  • De Rojas, Itziar|||0000-0002-2148-381X
  • Moreno-Grau, Sonia
  • Tesi, Niccolo|||0000-0002-1413-5091
  • Grenier-Boley, Benjamin
  • Andrade, Victor|||0000-0003-0682-269X
  • Jansen, Iris E.|||0000-0003-1901-8131
  • Pedersen, Nancy L.|||0000-0001-8057-3543
  • Stringa, Najada|||0000-0001-6350-452X
  • Zettergren, Anna|||0000-0002-7182-8417
  • Hernández, Isabel|||0000-0001-8119-393X
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Antúnez, Carmen
  • Antonell, Anna|||0000-0002-3286-8459
  • Tankard, Rick M.|||0000-0002-8847-9401
  • Bis, Joshua C.|||0000-0002-3409-1110
  • Sims, Rebecca|||0000-0002-3885-1199
  • Bellenguez, Céline|||0000-0002-1240-7874
  • Quintela, Inés|||0000-0002-0239-7975
  • González-Perez, Antonio
  • Calero, Miguel|||0000-0001-5366-3324
  • Franco-Macías, Emilio|||0000-0003-4186-1037
  • Macías, Juan|||0000-0002-4778-790X
  • Blesa, Rafael|||0000-0003-4026-2884
  • Cervera Carles, Laura|||0000-0003-2286-200X
  • Mendez-Gonzalez, Manuel|||0000-0002-5218-0774
  • Frank García, Ana
  • Royo, Jose Luís
  • Moreno, Fermin|||0000-0001-5200-3164
  • Huerto Vilas, Raquel
  • Baquero, Miquel|||0000-0002-6861-1831
  • Diez-Fairen, Monica|||0000-0003-1882-0309
  • Lage, Carmen|||0000-0003-1703-121X
  • García-Madrona, Sebastián
  • García-González, Pablo|||0000-0003-0125-5403
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Valero, Sergi|||0000-0002-6599-948X
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Ullgren, Abbe
  • Naj, Adam C.|||0000-0002-9621-2942
  • Lemstra, Afina W.|||0000-0002-8933-3260
  • Benaque, Alba
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Benussi, Alberto|||0000-0002-8703-6940
  • Rábano, Alberto|||0000-0001-9320-6566
  • Padovani, Alessandro|||0000-0002-0119-3639
  • Squassina, Alessio|||0000-0001-7415-7607
  • de Mendonça, Alexandre|||0000-0002-0488-1453
  • Arias Pastor, Alfonso
  • Kok, Almar A. L.
  • Meggy, Alun
  • Pastor, Ana Belén|||0000-0001-9637-4688
  • Espinosa, Ana|||0000-0001-7399-3267
  • Corma Gómez, Anaïs|||0000-0002-1078-0237
  • Martín Montes, Angel|||0000-0002-1694-786X
  • Sanabria, Ángela|||0000-0002-7501-9895
  • DeStefano, Anita L.|||0000-0002-9335-2819
  • Schneider, Anja|||0000-0001-9540-8700
  • Haapasalo, Annakaisa|||0000-0003-0959-2957
  • Kinhult Ståhlbom, Anne
  • Tybjærg-Hansen, Anne
  • Hartmann, Annette M.
  • Spottke, Annika
  • Corbatón-Anchuelo, Arturo
  • Rongve, Arvid|||0000-0002-0476-4134
  • Borroni, Barbara|||0000-0001-9340-9814
  • Arosio, Beatrice|||0000-0002-0615-3580
  • Nacmias, Benedetta|||0000-0001-9338-9040
  • Nordestgaard, Børge G.|||0000-0002-1954-7220
  • Kunkle, Brian W.
  • Charbonnier, Camille|||0000-0003-1172-0196
  • Abdelnour, Carla|||0000-0002-7636-9758
  • Masullo, Carlo|||0000-0001-7798-3410
  • Martínez Rodríguez, Carmen
  • Muñoz-Fernandez, Carmen
  • Dufouil, Carole|||0000-0003-2442-4476
  • Graff, Caroline|||0000-0002-9949-2951
  • Ferreira, Catarina B.
  • Chillotti, Caterina
  • Reynolds, Chandra A.|||0000-0001-6502-7173
  • Fenoglio, Chiara|||0000-0001-6332-4721
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Clark, Christopher|||0000-0001-7210-7702
  • Pisanu, Claudia|||0000-0002-9151-4319
  • Satizabal, Claudia L.|||0000-0002-1115-4430
  • Holmes, Clive
  • Buiza-Rueda, Dolores|||0000-0002-3504-9299
  • Aarsland, Dag|||0000-0001-6314-216X
  • Rujescu, Dan|||0000-0002-1432-313X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Galimberti, Daniela|||0000-0002-9284-5953
  • Wallon, David|||0000-0002-2634-7198
  • Seripa, Davide|||0000-0001-7331-0470
  • Grünblatt, Edna|||0000-0001-8505-7265
  • Dardiotis, Efthimios|||0000-0003-2957-641X
  • Düzel, Emrah
  • Scarpini, Elio|||0000-0002-6395-2119
  • Conti, Elisa
  • Rubino, Elisa|||0000-0002-7553-7553
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Duron, Emmanuelle
  • Boerwinkle, Eric|||0000-0001-8813-0544
  • Ferri, Evelyn
  • Tagliavini, Fabrizio|||0000-0003-1039-7315
  • Küçükali, Fahri
  • Pasquier, Florence|||0000-0001-9880-9788
  • Sánchez García, Florentino
  • Mangialasche, Francesca
  • Jessen, Frank
  • Nicolas, Gael|||0000-0001-9391-7800
  • Selbæk, Geir|||0000-0001-6511-8219
  • Ortega Linares, Gemma|||0000-0002-7479-4072
  • Chene, Geneviève|||0000-0002-8368-6460
  • Hadjigeorgiou, Georgios
  • Rossi, Giacomina|||0000-0001-6680-2725
  • Spalletta, Gianfranco|||0000-0002-7432-4249
  • Giaccone, Giorgio|||0000-0002-4803-0802
  • Grande, Giulia
  • Binetti, Giuliano|||0000-0003-2759-5844
  • Papenberg, Goran
  • Hampel, Harald
  • Bailly, Henri
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Soininen, Hilkka|||0000-0002-2785-9937
  • Karlsson, Ida K.
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Appollonio, Ildebrando
  • Giegling, Ina
  • Skoog, Ingmar
  • Saltvedt, Ingvild|||0000-0002-7897-9808
  • Rainero, Innocenzo|||0000-0001-6074-9628
  • Rosas Allende, Irene
  • Hort, Jakub|||0000-0002-1080-3726
  • Diehl-Schmid, Janine|||0000-0002-7745-1382
  • Van Dongen, Jasper|||0000-0001-5599-0046
  • Vidal, Jean-Sébastien|||0000-0001-6770-0720
  • Lehtisalo, Jenni
  • Wiltfang, Jens
  • Thomassen, Jesper Qvist|||0000-0003-3484-9531
  • Kornhuber, Johannes|||0000-0002-8096-3987
  • Haines, Jonathan L.|||0000-0002-4351-4728
  • Vogelgsang, Jonathan|||0000-0001-9326-8193
  • Pineda, Juan A.|||0000-0002-3751-0296
  • Fortea, Juan|||0000-0002-1340-638X
  • Popp, Julius|||0000-0002-0068-0312
  • Deckert, Jürgen|||0000-0003-1008-4650
  • Buerger, Katharina
  • Morgan, Kevin|||0000-0002-8217-2396
  • Fließbach, Klaus
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Kilander, Lena
  • Weinhold, Leonie
  • Farrer, Lindsay A.|||0000-0001-5533-4225
  • Wang, Li-San
  • Kleineidam, Luca
  • Farotti, Lucia
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Tremolizzo, Lucio|||0000-0003-0473-6560
  • Hausner, Lucrezia|||0000-0001-9009-2356
  • Benussi, Luisa|||0000-0003-2836-8141
  • Froelich, Lutz|||0000-0003-1494-0813
  • Ikram, M. Arfan|||0000-0003-0372-8585
  • Deniz Naranjo, M. Cándida
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Rosende-Roca, Maitée|||0000-0003-1778-8175
  • Löwenmark, Malin
  • Hulsman, Marc|||0000-0002-9889-3606
  • Spallazzi, Marco|||0000-0002-8091-2063
  • Pericak-Vance, Margaret A.|||0000-0001-7283-8804
  • Esiri, Margaret
  • Bernal Sánchez-Arjona, María
  • Dalmasso, Maria Carolina|||0000-0002-4901-9955
  • Martínez-Larrad, María Teresa
  • Arcaro, Marina|||0000-0002-3821-0682
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Fernández-Fuertes, Marta
  • Dichgans, Martin|||0000-0002-0654-387X
  • Ingelsson, Martin|||0000-0001-5466-8370
  • Herrmann, Martin J.|||0000-0001-9970-2122
  • Scherer, Martin
  • Vyhnalek, Martin
  • Kosmidis, Mary H.
  • Yannakoulia, Mary
  • Schmid, Matthias
  • Ewers, Michael|||0000-0001-5231-1714
  • Heneka, Michael|||0000-0003-4996-1630
  • Wagner, Michael
  • Scamosci, Michela
  • Kivipelto, Miia
  • Hiltunen, Mikko|||0000-0003-3566-4096
  • Zulaica, Miren
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Fornage, Myriam|||0000-0003-0677-8158
  • Roberto Herrero, Natalia|||0000-0002-5391-2711
  • van Schoor, Natasja M.
  • Seidu, Nazib M.
  • Banaj, Nerisa|||0000-0002-6317-8549
  • Armstrong, Nicola|||0000-0002-4477-293X
  • Scarmeas, Nikolaos|||0000-0001-6453-8908
  • Scherbaum, Norbert|||0000-0003-1759-6990
  • Goldhardt, Oliver
  • Hanon, Olivier|||0000-0002-4697-122X
  • Peters, Oliver|||0000-0003-0568-2998
  • Skrobot, Olivia Anna
  • Quenez, Olivier|||0000-0002-8273-8505
  • Lerch, Ondrej
  • Bossù, Paola|||0000-0002-1432-0078
  • Caffarra, Paolo
  • Dionigi Rossi, Paolo
  • Sakka, Paraskevi
  • Hoffmann, Per|||0000-0002-6573-983X
  • Holmans, Peter|||0000-0003-0870-9412
  • Fischer, Peter
  • Riederer, Peter
  • Yang, Qiong|||0000-0002-3658-1375
  • Marshall, Rachel
  • Kalaria, Rajesh N.
  • Mayeux, Richard|||0000-0001-6519-9696
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • Cecchetti, Roberta
  • Ghidoni, Roberta|||0000-0002-7691-1957
  • Frikke-Schmidt, Ruth|||0000-0003-4084-5027
  • Sorbi, Sandro|||0000-0002-0380-6670
  • Hägg, Sara|||0000-0002-2452-1500
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Helisalmi, Seppo
  • Botne Sando, Sigrid
  • Kern, Silke
  • Archetti, Silvana
  • Boschi, Silvia|||0000-0003-1610-1917
  • Fostinelli, Silvia
  • Gil-Navarro, Silvia|||0000-0001-9921-9042
  • Mendoza, Silvia
  • Mead, Simon|||0000-0002-4326-1468
  • Ciccone, Simona
  • Djurovic, Srdjan|||0000-0002-8140-8061
  • Heilmann-Heimbach, Stefanie|||0000-0003-1057-465X
  • Riedel-Heller, Steffi|||0000-0003-4321-6090
  • Kuulasmaa, Teemu|||0000-0002-1795-7314
  • del Ser, Teodoro|||0000-0001-9806-7083
  • Lebouvier, Thibaud
  • Polak, Thomas
  • Ngandu, Tiia
  • Grimmer, Timo
  • Bessi, Valentina|||0000-0002-6176-3584
  • Escott-Price, Valentina|||0000-0003-1784-5483
  • Giedraitis, Vilmantas|||0000-0003-3423-2021
  • Deramecourt, Vincent
  • Maier, Wolfgang
  • Jian, Xueqiu
  • Pijnenburg, Yolande|||0000-0003-2464-1905
  • Kehoe, Patrick|||0000-0002-7542-1139
  • García-Ribas, Guillermo
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Pastor, Pau|||0000-0002-7493-8777
  • Pérez-Tur, Jordi|||0000-0002-9111-1712
  • Piñol-Ripoll, Gerard
  • Lopez de Munain, Adolfo|||0000-0002-9509-4032
  • García-Alberca, Jose María|||0000-0003-2951-6644
  • Bullido, María J.|||0000-0002-6477-1117
  • Alvarez, Victoria|||0000-0002-1916-2523
  • Lleó, Alberto|||0000-0002-2568-5478
  • Real, Luis M.|||0000-0003-4932-7429
  • Mir, Pablo|||0000-0003-1656-302X
  • Medina, Miguel|||0000-0002-7016-5340
  • Scheltens, Philip|||0000-0002-1046-6408
  • Holstege, Henne|||0000-0002-7688-3087
  • Marquié, Marta|||0000-0002-0660-0950
  • Sáez, María Eugenia|||0000-0001-9299-2534
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Amouyel, Philippe|||0000-0001-9088-234X
  • Schellenberg, Gerard D.
  • Williams, Julie|||0000-0002-4069-0259
  • Seshadri, Sudha|||0000-0001-6135-2622
  • van Duijn, Cornelia M.|||0000-0002-2374-9204
  • Mather, Karen A.|||0000-0003-4143-8941
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Serrano-Ríos, Manuel
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Blennow, Kaj|||0000-0002-1890-4193
  • Huisman, Martijn A.
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Boada, Mercè|||0000-0003-2617-3009
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Lambert, Jean-Charles|||0000-0003-0829-7817
  • van der Lee, Sven J.|||0000-0003-1606-8643
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease. Known genetic loci account for only a fraction of the genetic contribution to Alzheimer's disease. Here, the authors have performed a large genome-wide meta-analysis comprising 409,435 individuals to discover 6 new loci and demonstrate the efficacy of an Alzheimer's disease polygenic risk score.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Macular vessel density in the superficial plexus is not associated to cerebrospinal fluid core biomarkers for Alzheimer's disease in individuals with mild cognitive impairment, The NORFACE cohort

  • Marquié, Marta|||0000-0002-0660-0950
  • García-Sánchez, Ainhoa
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Martínez, Joan|||0000-0001-7962-709X
  • Castilla Marti, Miguel|||0000-0003-1886-3536
  • Castilla-Martí, Luis|||0000-0002-7239-5289
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • De Rojas, Itziar|||0000-0002-2148-381X
  • García-González, Pablo|||0000-0003-0125-5403
  • Puerta, Raquel|||0000-0002-1191-5893
  • Olivé Roig, Clàudia|||0000-0002-9438-5639
  • Cano, Amanda|||0000-0001-9567-4283
  • Hernández, Isabel|||0000-0001-8119-393X
  • Rosende-Roca, Maitée|||0000-0003-1778-8175
  • Vargas, Liliana|||0000-0001-5685-5903
  • Tartari, Juan Pablo
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Bojaryn, Urszula
  • Ricciardi, Mario
  • Ariton, Diana María|||0000-0002-6035-5466
  • Pytel, Vanesa
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Ortega Linares, Gemma|||0000-0002-7479-4072
  • Espinosa, Ana|||0000-0001-7399-3267
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Sanabria, Ángela|||0000-0002-7501-9895
  • Muñoz, Nathalia
  • Lleonart, Núria
  • Aguilera, Núria
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Valero, Sergi|||0000-0002-6599-948X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Boada, Mercè|||0000-0003-2617-3009
Optical coherence tomography angiography (OCT-A) is a novel method in the dementia field that allows the detection of retinal vascular changes. The comparison of OCT-A measures with established Alzheimer's disease (AD)-related biomarkers is essential to validate the former as a marker of cerebrovascular impairment in the AD continuum. We aimed to investigate the association of macular vessel density (VD) in the superficial plexus quantified by OCT-A with the AT(N) classification based on cerebrospinal fluid (CSF) Aβ1-42, p181-tau and t-tau measurements in individuals with mild cognitive impairment (MCI). Clinical, demographic, ophthalmological, OCT-A and CSF core biomarkers for AD data from the Neuro-ophthalmology Research at Fundació ACE (NORFACE) project were analyzed. Differences in macular VD in four quadrants (superior, nasal, inferior, and temporal) among three AT(N) groups [Normal, Alzheimer and Suspected non-Alzheimer pathology (SNAP)] were assessed in a multivariate regression model, adjusted for age, APOE ε4 status, hypertension, diabetes mellitus, dyslipidemia, heart disease, chronic obstructive pulmonary disease and smoking habit, using the Normal AT(N) group as the reference category. The study cohort comprised 144 MCI participants: 66 Normal AT(N), 45 Alzheimer AT(N) and 33 SNAP AT(N). Regression analysis showed no significant association of the AT(N) groups with any of the regional macular VD measures (all, p.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment

  • Cano, Amanda|||0000-0001-9567-4283
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Bernuz, Mireia|||0000-0002-2052-6902
  • Puerta, Raquel|||0000-0002-1191-5893
  • García-González, Pablo|||0000-0003-0125-5403
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Olivé Roig, Clàudia|||0000-0002-9438-5639
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Núñez-Llaves, Raúl|||0000-0002-6702-4774
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Valero, Sergi|||0000-0002-6599-948X
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Martín, Elvira
  • Martino-Adami, Pamela V.
  • Ettcheto, Miren|||0000-0002-4301-7297
  • Camins, Antoni|||0000-0002-1229-5956
  • Vivas, Assumpta
  • Gómez Chiari, Marta|||0000-0001-6726-1721
  • Tejero, Miguel Ángel
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Marquié, Marta|||0000-0002-0660-0950
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
In the clinical course of Alzheimer's disease (AD) development, the dementia phase is commonly preceded by a prodromal AD phase, which is mainly characterized by reaching the highest levels of Aβ and p-tau-mediated neuronal injury and a mild cognitive impairment (MCI) clinical status. Because of that, most AD cases are diagnosed when neuronal damage is already established and irreversible. Therefore, a differential diagnosis of MCI causes in these prodromal stages is one of the greatest challenges for clinicians. Blood biomarkers are emerging as desirable tools for pre-screening purposes, but the current results are still being analyzed and much more data is needed to be implemented in clinical practice. Because of that, plasma extracellular vesicles (pEVs) are gaining popularity as a new source of biomarkers for the early stages of AD development. To identify an exosome proteomics signature linked to prodromal AD, we performed a cross-sectional study in a cohort of early-onset MCI (EOMCI) patients in which 184 biomarkers were measured in pEVs, cerebrospinal fluid (CSF), and plasma samples using multiplex PEA technology of Olink© proteomics. The obtained results showed that proteins measured in pEVs from EOMCI patients with established amyloidosis correlated with CSF p-tau181 levels, brain ventricle volume changes, brain hyperintensities, and MMSE scores. In addition, the correlations of pEVs proteins with different parameters distinguished between EOMCI Aβ( +) and Aβ(-) patients, whereas the CSF or plasma proteome did not. In conclusion, our findings suggest that pEVs may be able to provide information regarding the initial amyloidotic changes of AD. Circulating exosomes may acquire a pathological protein signature of AD before raw plasma, becoming potential biomarkers for identifying subjects at the earliest stages of AD development.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Extracellular vesicles, the emerging mirrors of brain physiopathology

  • Cano, Amanda|||0000-0001-9567-4283
  • Ettcheto, Miren|||0000-0002-4301-7297
  • Bernuz, Mireia|||0000-0002-2052-6902
  • Puerta, Raquel|||0000-0002-1191-5893
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Sánchez-López, Elena|||0000-0003-2571-108X
  • Souto, Eliana B.
  • Camins, Antoni|||0000-0002-1229-5956
  • Martí, Mercè|||0000-0002-1846-0043
  • Pividori, María Isabel|||0000-0002-5266-7873
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
Extracellular vesicles are secreted by a wide variety of cells, and their primary functions include intercellular communication, immune responses, human reproduction, and synaptic plasticity. Their molecular cargo reflects the physiological processes that their cells of origin are undergoing. Thus, many studies have suggested that extracellular vesicles could be a promising biomarker tool for many diseases, mainly due to their biological relevance and easy accessibility to a broad range of body fluids. Moreover, since their biological composition leads them to cross the blood-brain barrier bidirectionally, growing evidence points to extracellular vesicles as emerging mirrors of brain diseases processes. In this regard, this review explores the biogenesis and biological functions of extracellular vesicles, their role in different physiological and pathological processes, their potential in clinical practice, and the recent outstanding studies about the role of exosomes in major human brain diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or brain tumors.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease, An international overview

  • Delaby, Constance|||0000-0002-8606-6814
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Blennow, Kaj|||0000-0002-1890-4193
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Arisi, Ivan
  • Amar, Elodie Bouaziz
  • Beaume, Anne
  • Bedel, Aurelie
  • Bellomo, Giovanni|||0000-0003-0456-5650
  • Bigot-Corbel, Edith
  • Bjerke, Maria
  • Blanc-Quintin, Marie-Céline
  • Boada, Mercè|||0000-0003-2617-3009
  • Bousiges, Olivier|||0000-0001-6786-3191
  • Chapman, Miles D.
  • DeMarco, Mari L.
  • D'Onofrio, Mara
  • Dumurgier, Julien
  • Dufour-Rainfray, Diane
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Esselmann, Hermann
  • Fogli, Anne
  • Gabelle, Audrey
  • Galloni, Elisabetta
  • Gondolf, Clémentine
  • Grandhomme, Frédérique
  • Grau-Rivera, Oriol|||0000-0002-4730-5341
  • Hart, Melanie
  • Ikeuchi, Takeshi|||0000-0001-8828-8085
  • Jeromin, Andreas
  • Kasuga, Kensaku
  • Keshavan, Ashvini
  • Khalil, Michael|||0000-0002-5350-3328
  • Körtvelyessy, Peter
  • Kulczynska-Przybik, Agnieszka
  • Laplanche, Jean-Louis
  • Lewczuk, Piotr|||0000-0002-8101-6535
  • Li, Qiao-Xin
  • Lleó, Alberto|||0000-0002-2568-5478
  • Malaplate, Catherine
  • Marquié, Marta|||0000-0002-0660-0950
  • Masters, Colin L.
  • Mroczko, Barbara
  • Nogueira, Léonor
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Otto, Markus
  • Oudart, Jean-Baptiste
  • Paquet, Claire|||0000-0002-2273-7316
  • Paoletti, Federico Paolini
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Perret-Liaudet, Armand
  • Peoc'h, Katell
  • Poesen, Koen
  • Puig-Pijoan, Albert|||0000-0002-9848-3711
  • Quadrio, Isabelle
  • Quillard-Muraine, Muriel
  • Rucheton, Benoit
  • Schraen, Susanna
  • Schott, Jonathan M.|||0000-0003-2059-024X
  • Shaw, Leslie M.
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Tumani, Hayrettin|||0000-0002-1647-6201
  • Udeh-Momoh, Chinedu|||0000-0002-7357-4692
  • Vaudran, Lucie
  • Verbeek, Marcel M.
  • Verde, Federico
  • Vermunt, Lisa
  • Vogelgsang, Jonathan|||0000-0001-9326-8193
  • Wiltfang, Jens
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Lehmann, Sylvain|||0000-0001-6117-562X
The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests. We obtained a description of (pre-)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients. The (pre-)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis. This is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Author Correction, Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

  • De Rojas, Itziar|||0000-0002-2148-381X
  • Moreno-Grau, Sonia
  • Tesi, Niccolo|||0000-0002-1413-5091
  • Grenier-Boley, Benjamin
  • Andrade, Victor|||0000-0003-0682-269X
  • Jansen, Iris E.|||0000-0003-1901-8131
  • Pedersen, Nancy L.|||0000-0001-8057-3543
  • Stringa, Najada|||0000-0001-6350-452X
  • Zettergren, Anna|||0000-0002-7182-8417
  • Hernández, Isabel|||0000-0001-8119-393X
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Antúnez, Carmen
  • Antonell, Anna|||0000-0002-3286-8459
  • Tankard, Rick M.|||0000-0002-8847-9401
  • Bis, Joshua C.|||0000-0002-3409-1110
  • Sims, Rebecca|||0000-0002-3885-1199
  • Bellenguez, Céline|||0000-0002-1240-7874
  • Quintela, Inés|||0000-0002-0239-7975
  • González-Perez, Antonio
  • Calero, Miguel|||0000-0001-5366-3324
  • Franco-Macías, Emilio|||0000-0003-4186-1037
  • Macías, Juan|||0000-0002-4778-790X
  • Blesa, Rafael|||0000-0003-4026-2884
  • Cervera Carles, Laura|||0000-0003-2286-200X
  • Mendez-Gonzalez, Manuel|||0000-0002-5218-0774
  • Frank García, Ana
  • Royo, Jose Luís
  • Moreno, Fermin|||0000-0001-5200-3164
  • Huerto Vilas, Raquel
  • Baquero, Miquel|||0000-0002-6861-1831
  • Diez-Fairen, Monica|||0000-0003-1882-0309
  • Lage, Carmen|||0000-0003-1703-121X
  • García-Madrona, Sebastián
  • García-González, Pablo|||0000-0003-0125-5403
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Valero, Sergi|||0000-0002-6599-948X
  • Sotolongo Grau, Oscar|||0000-0002-9679-0670
  • Ullgren, Abbe
  • Naj, Adam C.|||0000-0002-9621-2942
  • Lemstra, Afina W.|||0000-0002-8933-3260
  • Benaque, Alba
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Benussi, Alberto|||0000-0002-8703-6940
  • Rábano, Alberto|||0000-0001-9320-6566
  • Padovani, Alessandro|||0000-0002-0119-3639
  • Squassina, Alessio|||0000-0001-7415-7607
  • de Mendonça, Alexandre|||0000-0002-0488-1453
  • Arias Pastor, Alfonso
  • Kok, Almar A. L.
  • Meggy, Alun
  • Pastor, Ana Belén|||0000-0001-9637-4688
  • Espinosa, Ana|||0000-0001-7399-3267
  • Corma Gómez, Anaïs|||0000-0002-1078-0237
  • Martín Montes, Angel|||0000-0002-1694-786X
  • Sanabria, Ángela|||0000-0002-7501-9895
  • DeStefano, Anita L.|||0000-0002-9335-2819
  • Schneider, Anja|||0000-0001-9540-8700
  • Haapasalo, Annakaisa|||0000-0003-0959-2957
  • Kinhult Ståhlbom, Anne
  • Tybjærg-Hansen, Anne
  • Hartmann, Annette M.
  • Spottke, Annika
  • Corbatón-Anchuelo, Arturo
  • Rongve, Arvid|||0000-0002-0476-4134
  • Borroni, Barbara|||0000-0001-9340-9814
  • Arosio, Beatrice|||0000-0002-0615-3580
  • Nacmias, Benedetta|||0000-0001-9338-9040
  • Nordestgaard, Børge G.|||0000-0002-1954-7220
  • Kunkle, Brian W.
  • Charbonnier, Camille|||0000-0003-1172-0196
  • Abdelnour, Carla|||0000-0002-7636-9758
  • Masullo, Carlo|||0000-0001-7798-3410
  • Martínez Rodríguez, Carmen
  • Muñoz-Fernandez, Carmen
  • Dufouil, Carole|||0000-0003-2442-4476
  • Graff, Caroline|||0000-0002-9949-2951
  • Ferreira, Catarina B.
  • Chillotti, Caterina
  • Reynolds, Chandra A.|||0000-0001-6502-7173
  • Fenoglio, Chiara|||0000-0001-6332-4721
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Clark, Christopher|||0000-0001-7210-7702
  • Pisanu, Claudia|||0000-0002-9151-4319
  • Satizabal, Claudia L.|||0000-0002-1115-4430
  • Holmes, Clive
  • Buiza-Rueda, Dolores|||0000-0002-3504-9299
  • Aarsland, Dag|||0000-0001-6314-216X
  • Rujescu, Dan|||0000-0002-1432-313X
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Galimberti, Daniela|||0000-0002-9284-5953
  • Wallon, David|||0000-0002-2634-7198
  • Seripa, Davide|||0000-0001-7331-0470
  • Grünblatt, Edna|||0000-0001-8505-7265
  • Dardiotis, Efthimios|||0000-0003-2957-641X
  • Düzel, Emrah
  • Scarpini, Elio|||0000-0002-6395-2119
  • Conti, Elisa
  • Rubino, Elisa|||0000-0002-7553-7553
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Duron, Emmanuelle
  • Boerwinkle, Eric|||0000-0001-8813-0544
  • Ferri, Evelyn
  • Tagliavini, Fabrizio|||0000-0003-1039-7315
  • Küçükali, Fahri
  • Pasquier, Florence|||0000-0001-9880-9788
  • Sánchez García, Florentino
  • Mangialasche, Francesca
  • Jessen, Frank
  • Nicolas, Gael|||0000-0001-9391-7800
  • Selbæk, Geir|||0000-0001-6511-8219
  • Ortega, Gemma
  • Chene, Geneviève|||0000-0002-8368-6460
  • Hadjigeorgiou, Georgios
  • Rossi, Giacomina|||0000-0001-6680-2725
  • Spalletta, Gianfranco|||0000-0002-7432-4249
  • Giaccone, Giorgio|||0000-0002-4803-0802
  • Grande, Giulia
  • Binetti, Giuliano|||0000-0003-2759-5844
  • Papenberg, Goran
  • Hampel, Harald
  • Bailly, Henri
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Soininen, Hilkka|||0000-0002-2785-9937
  • Karlsson, Ida K.
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Appollonio, Ildebrando
  • Giegling, Ina
  • Skoog, Ingmar
  • Saltvedt, Ingvild|||0000-0002-7897-9808
  • Rainero, Innocenzo|||0000-0001-6074-9628
  • Rosas Allende, Irene
  • Hort, Jakub|||0000-0002-1080-3726
  • Diehl-Schmid, Janine|||0000-0002-7745-1382
  • Van Dongen, Jasper|||0000-0001-5599-0046
  • Vidal, Jean-Sébastien|||0000-0001-6770-0720
  • Lehtisalo, Jenni
  • Wiltfang, Jens
  • Thomassen, Jesper Qvist|||0000-0003-3484-9531
  • Kornhuber, Johannes|||0000-0002-8096-3987
  • Haines, Jonathan L.|||0000-0002-4351-4728
  • Vogelgsang, Jonathan|||0000-0001-9326-8193
  • Pineda, Juan A.|||0000-0002-3751-0296
  • Fortea, Juan|||0000-0002-1340-638X
  • Popp, Julius|||0000-0002-0068-0312
  • Deckert, Jürgen|||0000-0003-1008-4650
  • Buerger, Katharina
  • Morgan, Kevin|||0000-0002-8217-2396
  • Fließbach, Klaus
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Molina-Porcel, Laura|||0000-0003-4068-8578
  • Kilander, Lena
  • Weinhold, Leonie
  • Farrer, Lindsay A.|||0000-0001-5533-4225
  • Wang, Li-San
  • Kleineidam, Luca
  • Farotti, Lucia
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Tremolizzo, Lucio|||0000-0003-0473-6560
  • Hausner, Lucrezia|||0000-0001-9009-2356
  • Benussi, Luisa|||0000-0003-2836-8141
  • Froelich, Lutz|||0000-0003-1494-0813
  • Ikram, M. Arfan|||0000-0003-0372-8585
  • Deniz Naranjo, M. Cándida
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Rosende-Roca, Maitée|||0000-0003-1778-8175
  • Löwenmark, Malin
  • Hulsman, Marc|||0000-0002-9889-3606
  • Spallazzi, Marco|||0000-0002-8091-2063
  • Pericak-Vance, Margaret A.|||0000-0001-7283-8804
  • Esiri, Margaret
  • Bernal Sánchez-Arjona, María
  • Dalmasso, Maria Carolina|||0000-0002-4901-9955
  • Martínez-Larrad, María Teresa
  • Arcaro, Marina|||0000-0002-3821-0682
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Fernández-Fuertes, Marta
  • Dichgans, Martin|||0000-0002-0654-387X
  • Ingelsson, Martin|||0000-0001-5466-8370
  • Herrmann, Martin J.|||0000-0001-9970-2122
  • Scherer, Martin
  • Vyhnalek, Martin
  • Kosmidis, Mary H.
  • Yannakoulia, Mary
  • Schmid, Matthias
  • Ewers, Michael|||0000-0001-5231-1714
  • Heneka, Michael|||0000-0003-4996-1630
  • Wagner, Michael
  • Scamosci, Michela
  • Kivipelto, Miia
  • Hiltunen, Mikko|||0000-0003-3566-4096
  • Zulaica, Miren
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Fornage, Myriam|||0000-0003-0677-8158
  • Roberto Herrero, Natalia|||0000-0002-5391-2711
  • van Schoor, Natasja M.
  • Seidu, Nazib M.
  • Banaj, Nerisa|||0000-0002-6317-8549
  • Armstrong, Nicola|||0000-0002-4477-293X
  • Scarmeas, Nikolaos|||0000-0001-6453-8908
  • Scherbaum, Norbert|||0000-0003-1759-6990
  • Goldhardt, Oliver
  • Hanon, Olivier|||0000-0002-4697-122X
  • Peters, Oliver|||0000-0003-0568-2998
  • Skrobot, Olivia Anna
  • Quenez, Olivier|||0000-0002-8273-8505
  • Lerch, Ondrej
  • Bossù, Paola|||0000-0002-1432-0078
  • Caffarra, Paolo
  • Dionigi Rossi, Paolo
  • Sakka, Paraskevi
  • Mecocci, Patrizia|||0000-0003-0729-5246
  • Hoffmann, Per|||0000-0002-6573-983X
  • Holmans, Peter|||0000-0003-0870-9412
  • Fischer, Peter
  • Riederer, Peter
  • Yang, Qiong|||0000-0002-3658-1375
  • Marshall, Rachel
  • Kalaria, Rajesh N.
  • Mayeux, Richard|||0000-0001-6519-9696
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • Cecchetti, Roberta
  • Ghidoni, Roberta|||0000-0002-7691-1957
  • Frikke-Schmidt, Ruth|||0000-0003-4084-5027
  • Sorbi, Sandro|||0000-0002-0380-6670
  • Hägg, Sara|||0000-0002-2452-1500
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Helisalmi, Seppo
  • Botne Sando, Sigrid
  • Kern, Silke
  • Archetti, Silvana
  • Boschi, Silvia|||0000-0003-1610-1917
  • Fostinelli, Silvia
  • Gil-Navarro, Silvia|||0000-0001-9921-9042
  • Mendoza, Silvia
  • Mead, Simon|||0000-0002-4326-1468
  • Ciccone, Simona
  • Djurovic, Srdjan|||0000-0002-8140-8061
  • Heilmann-Heimbach, Stefanie|||0000-0003-1057-465X
  • Riedel-Heller, Steffi|||0000-0003-4321-6090
  • Kuulasmaa, Teemu|||0000-0002-1795-7314
  • del Ser, Teodoro|||0000-0001-9806-7083
  • Lebouvier, Thibaud
  • Polak, Thomas
  • Ngandu, Tiia
  • Grimmer, Timo
  • Bessi, Valentina|||0000-0002-6176-3584
  • Escott-Price, Valentina|||0000-0003-1784-5483
  • Giedraitis, Vilmantas|||0000-0003-3423-2021
  • Deramecourt, Vincent
  • Maier, Wolfgang
  • Jian, Xueqiu
  • Pijnenburg, Yolande|||0000-0003-2464-1905
  • Kehoe, Patrick|||0000-0002-7542-1139
  • García-Ribas, Guillermo
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Pastor, Pau|||0000-0002-7493-8777
  • Pérez-Tur, Jordi|||0000-0002-9111-1712
  • Piñol-Ripoll, Gerard
  • Lopez de Munain, Adolfo|||0000-0002-9509-4032
  • García-Alberca, Jose María|||0000-0003-2951-6644
  • Bullido, María J.|||0000-0002-6477-1117
  • Alvarez, Victoria|||0000-0002-1916-2523
  • Lleó, Alberto|||0000-0002-2568-5478
  • Real, Luis M.|||0000-0003-4932-7429
  • Mir, Pablo|||0000-0003-1656-302X
  • Medina, Miguel|||0000-0002-7016-5340
  • Scheltens, Philip|||0000-0002-1046-6408
  • Holstege, Henne|||0000-0002-7688-3087
  • Marquié, Marta|||0000-0002-0660-0950
  • Sáez, María Eugenia|||0000-0001-9299-2534
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Amouyel, Philippe|||0000-0001-9088-234X
  • Schellenberg, Gerard D.
  • Williams, Julie|||0000-0002-4069-0259
  • Seshadri, Sudha|||0000-0001-6135-2622
  • van Duijn, Cornelia M.|||0000-0002-2374-9204
  • Mather, Karen A.|||0000-0003-4143-8941
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Serrano-Ríos, Manuel
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Blennow, Kaj|||0000-0002-1890-4193
  • Huisman, Martijn A.
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Boada, Mercè|||0000-0003-2617-3009
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Lambert, Jean-Charles|||0000-0003-0829-7817
  • van der Lee, Sven J.|||0000-0003-1606-8643
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers

  • Jansen, Iris E.|||0000-0003-1901-8131
  • van der Lee, Sven J.|||0000-0003-1606-8643
  • Gomez-Fonseca, Duber
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Dalmasso, Maria Carolina|||0000-0002-4901-9955
  • Grenier-Boley, Benjamin
  • Zettergren, Anna|||0000-0002-7182-8417
  • Mishra, Aniket|||0000-0002-8141-1543
  • Ali, Muhammad|||0000-0002-1399-6631
  • Andrade, Victor|||0000-0003-0682-269X
  • Bellenguez, Céline|||0000-0002-1240-7874
  • Kleineidam, Luca
  • Küçükali, Fahri
  • Sung, Ju Sung
  • Tesí, Niccolo
  • Vromen, Ellen|||0000-0001-7774-5500
  • Wightman, Douglas P.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Amouyel, Philippe|||0000-0001-9088-234X
  • Athanasiu, Lavinia
  • Bahrami, Shahram
  • Bailly, Henri
  • Belbin, Olivia|||0000-0002-6109-6371
  • Bergh, Sverre|||0000-0001-9593-2967
  • Bertram, Lars|||0000-0002-0108-124X
  • Biessels, Geert Jan|||0000-0001-6862-2496
  • Blennow, Kaj|||0000-0002-1890-4193
  • Blesa, Rafael|||0000-0003-4026-2884
  • Boada, Mercè|||0000-0003-2617-3009
  • Boland, Anne|||0000-0001-8789-5676
  • Buerger, K.
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Cervera Carles, Laura|||0000-0003-2286-200X
  • Chene, Geneviève|||0000-0002-8368-6460
  • Claassen, Jurgen|||0000-0002-1778-8151
  • Debette, Stéphanie|||0000-0001-8675-7968
  • Deleuze, Jean-Francois
  • De Deyn, Peter Paul|||0000-0002-2228-2964
  • Diehl-Schmid, Janine|||0000-0002-7745-1382
  • Djurovic, Srdjan|||0000-0002-8140-8061
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Dufouil, Carole|||0000-0003-2442-4476
  • Duron, Emmanuelle
  • Düzel, Emrah
  • Fladby, Tormod|||0000-0002-9984-9797
  • Fortea, Juan|||0000-0002-1340-638X
  • Froelich, Lutz|||0000-0003-1494-0813
  • García-González, Pablo|||0000-0003-0125-5403
  • Garcia-Martinez, María
  • Giegling, Ina
  • Goldhardt, Oliver
  • Gobom, Johan|||0000-0001-6193-6193
  • Grimmer, Timo
  • Haapasalo, Annakaisa|||0000-0003-0959-2957
  • Hampel, Harald
  • Hanon, Olivier|||0000-0002-4697-122X
  • Hausner, Lucrezia|||0000-0001-9009-2356
  • Heilmann-Heimbach, Stefanie|||0000-0003-1057-465X
  • Helisalmi, Seppo
  • Heneka, Michael|||0000-0003-4996-1630
  • Hernández, Isabel|||0000-0001-8119-393X
  • Herukka, Sanna-Kaisa|||0000-0003-3308-8662
  • Holstege, Henne|||0000-0002-7688-3087
  • Jarholm, Jonas
  • Kern, Silke
  • Knapskog, Anne-Brita
  • Koivisto, A.M.
  • Kornhuber, Johannes|||0000-0002-8096-3987
  • Kuulasmaa, Teemu|||0000-0002-1795-7314
  • Lage, Carmen|||0000-0003-1703-121X
  • Laske, Christoph
  • Leinonen, Ville|||0000-0002-4282-4687
  • Lewczuk, Piotr|||0000-0002-8101-6535
  • Lleó, Alberto|||0000-0002-2568-5478
  • Lopez de Munain, Adolfo|||0000-0002-9509-4032
  • López-Garcia, Sara
  • Maier, Wolfgang
  • Marquié, Marta|||0000-0002-0660-0950
  • Mol, Merel O.|||0000-0003-2533-2530
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • Moreno, Fermin|||0000-0001-5200-3164
  • Moreno-Grau, Sonia
  • Nicolas, Gael|||0000-0001-9391-7800
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Pålhaugen, Lene
  • Papma, Janne M.
  • Pasquier, Florence|||0000-0001-9880-9788
  • Perneczky, Robert|||0000-0003-1981-7435
  • Peters, Oliver|||0000-0003-0568-2998
  • Pijnenburg, Yolande A.L.
  • Popp, Julius|||0000-0002-0068-0312
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Pozueta, Ana
  • Priller, Josef|||0000-0001-7596-0979
  • Puerta, Raquel|||0000-0002-1191-5893
  • Quintela, Inés|||0000-0002-0239-7975
  • Ramakers, Inez
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Rujescu, Dan|||0000-0002-1432-313X
  • Saltvedt, Ingvild|||0000-0002-7897-9808
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Scheltens, Philip|||0000-0002-1046-6408
  • Scherbaum, Norbert|||0000-0003-1759-6990
  • Schmid, Matthias
  • Schneider, Anja|||0000-0001-9540-8700
  • Selbæk, Geir|||0000-0001-6511-8219
  • Selnes, Per
  • Shadrin, Alexey
  • Skoog, Ingmar
  • Soininen, Hilkka|||0000-0002-2785-9937
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Teipel, Stefan
  • Tijms, Betty M.|||0000-0002-2612-1797
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Van Dongen, Jasper|||0000-0001-5599-0046
  • van Swieten, John C.
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • Vidal, Jean-Sébastien|||0000-0001-6770-0720
  • Visser, Pieter Jelle|||0000-0001-8008-9727
  • Vogelgsang, Jonathan|||0000-0001-9326-8193
  • Waern, Margda|||0000-0002-8330-6915
  • Wagner, Michael
  • Wiltfang, Jens W.
  • Wittens, Mandy M.J.
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Zulaica, Miren
  • van Duijn, Cornelia M.|||0000-0002-2374-9204
  • Bjerke, Maria
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Jessen, Frank
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Pastor, Pau|||0000-0002-7493-8777
  • Hiltunen, Mikko|||0000-0003-3566-4096
  • Ingelsson, Martin|||0000-0001-5466-8370
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Cruchaga, Carlos|||0000-0002-0276-2899
  • Lambert, Jean-Charles|||0000-0003-0829-7817
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer's disease (AD) more directly than clinical diagnosis. Initiated by the European Alzheimer & Dementia Biobank (EADB), the largest collaborative effort on genetics underlying CSF biomarkers was established, including 31 cohorts with a total of 13,116 individuals (discovery n = 8074; replication n = 5042 individuals). Besides the APOE locus, novel associations with two other well-established AD risk loci were observed; CR1 was shown a locus for Aβ42 and BIN1 for pTau. GMNC and C16orf95 were further identified as loci for pTau, of which the latter is novel. Clustering methods exploring the influence of all known AD risk loci on the CSF protein levels, revealed 4 biological categories suggesting multiple Aβ42 and pTau related biological pathways involved in the etiology of AD. In functional follow-up analyses, GMNC and C16orf95 both associated with lateral ventricular volume, implying an overlap in genetic etiology for tau levels and brain ventricular volume.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Extracellular vesicles secreted by triple-negative breast cancer stem cells trigger premetastatic niche remodeling and metastatic growth in the lungs

  • González-Callejo, Patricia|||0000-0003-2963-4878
  • Gener, Petra|||0000-0002-2250-570X
  • Díaz Riascos, Zamira Vanessa|||0000-0003-1595-618X
  • Conti, Sefora|||0000-0002-0616-0692
  • Cámara-Sánchez, Patricia|||0000-0003-1958-9735
  • Riera Brillas, Roger|||0000-0001-9406-597X
  • Mancilla, Sandra|||0000-0002-9681-3588
  • García-Gabilondo, Miguel|||0000-0002-2015-2621
  • Peg, Vicente|||0000-0002-5203-6166
  • Arango, Diego|||0000-0003-2953-3284
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Labernadie, Anna|||0000-0001-5768-5088
  • Trepat, Xavier|||0000-0002-7621-5214
  • Albertazzi, Lorenzo|||0000-0002-6837-0812
  • Schwartz, Simon|||0000-0001-8297-7971
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Abasolo, Ibane|||0000-0001-5970-6276
Tumor secreted extracellular vesicles (EVs) are potent intercellular signaling platforms. They are responsible for the accommodation of the premetastatic niche (PMN) to support cancer cell engraftment and metastatic growth. However, complex cancer cell composition within the tumor increases also the heterogeneity among cancer secreted EVs subsets, a functional diversity that has been poorly explored. This phenomenon is particularly relevant in highly plastic and heterogenous triple-negative breast cancer (TNBC), in which a significant representation of malignant cancer stem cells (CSCs) is displayed. Herein, we selectively isolated and characterized EVs from CSC or differentiated cancer cells (DCC; EVs and EVs, respectively) from the MDA-MB-231 TNBC cell line. Our results showed that EVs and EVs contain distinct bioactive cargos and therefore elicit a differential effect on stromal cells in the TME. Specifically, EVs activated secretory cancer associated fibroblasts (CAFs), triggering IL-6/IL-8 signaling and sustaining CSC phenotype maintenance. Complementarily, EVs promoted the activation of α-SMA+ myofibroblastic CAFs subpopulations and increased the endothelial remodeling, enhancing the invasive potential of TNBC cells in vitro and in vivo. In addition, solely the EVs mediated signaling prompted the transformation of healthy lungs into receptive niches able to support metastatic growth of breast cancer cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort

  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • García-González, Pablo|||0000-0003-0125-5403
  • Valero, Sergi|||0000-0002-6599-948X
  • Montrreal Navarro, Laura|||0000-0002-0010-645X
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Hernández, Isabel|||0000-0001-8119-393X
  • Rosende-Roca, Maitée|||0000-0003-1778-8175
  • Vargas, Liliana|||0000-0001-5685-5903
  • Tartari, Juan Pablo
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Bojaryn, Urszula
  • Narvaiza, Leire
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Pytel, Vanesa
  • Cano, Amanda|||0000-0001-9567-4283
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
Background: Clinical diagnosis of Alzheimer's disease (AD) increasingly incorporates CSF biomarkers. However, due to the intrinsic variability of the immunodetection techniques used to measure these biomarkers, establishing in-house cutoffs defining the positivity/negativity of CSF biomarkers is recommended. However, the cutoffs currently published are usually reported by using cross-sectional datasets, not providing evidence about its intrinsic prognostic value when applied to real-world memory clinic cases. Methods: We quantified CSF Aβ1-42, Aβ1-40, t-Tau, and p181Tau with standard INNOTEST® ELISA and Lumipulse G® chemiluminescence enzyme immunoassay (CLEIA) performed on the automated Lumipulse G600II. Determination of cutoffs included patients clinically diagnosed with probable Alzheimer's disease (AD, n = 37) and subjective cognitive decline subjects (SCD, n = 45), cognitively stable for 3 years and with no evidence of brain amyloidosis in 18F-Florbetaben-labeled positron emission tomography (FBB-PET). To compare both methods, a subset of samples for Aβ1-42 (n = 519), t-Tau (n = 399), p181Tau (n = 77), and Aβ1-40 (n = 44) was analyzed. Kappa agreement of single biomarkers and Aβ1-42/Aβ1-40 was evaluated in an independent group of mild cognitive impairment (MCI) and dementia patients (n = 68). Next, established cutoffs were applied to a large real-world cohort of MCI subjects with follow-up data available (n = 647). Results: Cutoff values of Aβ1-42 and t-Tau were higher for CLEIA than for ELISA and similar for p181Tau. Spearman coefficients ranged between 0.81 for Aβ1-40 and 0.96 for p181TAU. Passing-Bablok analysis showed a systematic and proportional difference for all biomarkers but only systematic for Aβ1-40. Bland-Altman analysis showed an average difference between methods in favor of CLEIA. Kappa agreement for single biomarkers was good but lower for the Aβ1-42/Aβ1-40 ratio. Using the calculated cutoffs, we were able to stratify MCI subjects into four AT(N) categories. Kaplan-Meier analyses of AT(N) categories demonstrated gradual and differential dementia conversion rates (p = 9.815). Multivariate Cox proportional hazard models corroborated these findings, demonstrating that the proposed AT(N) classifier has prognostic value. AT(N) categories are only modestly influenced by other known factors associated with disease progression. Conclusions: We established CLEIA and ELISA internal cutoffs to discriminate AD patients from amyloid-negative SCD individuals. The results obtained by both methods are not interchangeable but show good agreement. CLEIA is a good and faster alternative to manual ELISA for providing AT(N) classification of our patients. AT(N) categories have an impact on disease progression. AT(N) classifiers increase the certainty of the MCI prognosis, which can be instrumental in managing real-world MCI subjects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Differences in macular vessel density in the superficial plexus across cognitive impairment, the NORFACE cohort

  • Marquié, Marta|||0000-0002-0660-0950
  • Valero, Sergi|||0000-0002-6599-948X
  • Martínez, Joan|||0000-0001-7962-709X
  • Alarcón-Martín, Emilio|||0000-0002-0985-872X
  • García-Sánchez, Ainhoa
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Castilla Marti, Miguel|||0000-0003-1886-3536
  • Castilla-Martí, Luis|||0000-0002-7239-5289
  • Hernández, Isabel|||0000-0001-8119-393X
  • Rosende-Roca, Maitée|||0000-0003-1778-8175
  • Vargas, Liliana|||0000-0001-5685-5903
  • Tartari, Juan Pablo
  • Esteban de Antonio, Ester|||0000-0003-1965-6010
  • Bojaryn, Urszula
  • Pytel, Vanesa
  • Narvaiza, Leire
  • Alegret, Montserrat|||0000-0002-8164-9500
  • Ortega Linares, Gemma|||0000-0002-7479-4072
  • Espinosa, Ana|||0000-0001-7399-3267
  • Sanabria, Ángela|||0000-0002-7501-9895
  • Pérez-Cordón, Alba|||0000-0002-6028-0791
  • Lleonart, Núria
  • Muñoz, Nathalia
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Boada, Mercè|||0000-0003-2617-3009
Optical coherence tomography angiography (OCT-A) allows the detection of retinal vessel density (VD) loss, which is a reflection of brain vascular pathology. We aimed to investigate differences in macular VD in the superficial plexus in a large cohort of individuals cognitively unimpaired (CU), with mild cognitive impairment due to Alzheimer's disease (MCI-AD), MCI due to cerebrovascular pathology (MCI-Va), probable Alzheimer's disease dementia (ADD) and Vascular Dementia (VaD). Clinical, demographical, ophthalmological and OCT-A data from the Neuro-ophthalmology Research at Fundació ACE (NORFACE) project were analyzed. Differences of macular VD in four quadrants (superior, nasal, inferior and temporal) among the five diagnostic groups were assessed in a multivariate regression model, adjusted by age, sex, education, hypertension, diabetes mellitus, heart disease and stroke. The study cohort comprised 672 participants: 128 CU, 120 MCI-AD, 111 MCI-Va, 257 ADD and 56 VaD. Regression analysis showed a significantly higher VD in the temporal quadrant in MCI-AD compared to CU participants (49.05 ± 4.91 vs 47.27 ± 4.17, p = 0.02, d = 0.40), and a significantly lower VD in the inferior quadrant in MCI-Va compared to CU participants (48.70 ± 6.57 vs 51.27 ± 6.39, p = 0.02, d = 0.40). Individuals with heart disease presented significantly lower VD in the inferior quadrant than those without (p = 0.01). The interaction of sex and diagnosis had no effect in differentiating VD. Mini-Mental State Examination (MMSE) scores were not correlated to VD (all r < 0.16; p.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics

  • Ulldemolins, Anna|||0000-0001-8825-9436
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
  • Andrade, Fernanda|||0000-0002-4947-2346
  • Rafael, Diana|||0000-0003-3180-3028
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Gener, Petra|||0000-0002-2250-570X
  • Schwartz, Simon|||0000-0001-8297-7971
Advanced cancer is still considered an incurable disease because of its metastatic spread to distal organs and progressive gain of chemoresistance. Even though considerable treatment progress and more effective therapies have been achieved over the past years, recurrence in the long-term and undesired side effects are still the main drawbacks of current clinical protocols. Moreover, a majority of chemotherapeutic drugs are highly hydrophobic and need to be diluted in organic solvents, which cause high toxicity, in order to reach effective therapeutic dose. These limitations of conventional cancer therapies prompted the use of nanomedicine, the medical application of nanotechnology, to provide more effective and safer cancer treatment. Potential of nanomedicines to overcome resistance, ameliorate solubility, improve pharmacological profile, and reduce adverse effects of chemotherapeutical drugs is thus highly regarded. Their use in the clinical setting has increased over the last decade. Among the various existing nanosystems, nanoparticles have the ability to transform conventional medicine by reducing the adverse effects and providing a controlled release of therapeutic agents. Also, their small size facilitates the intracellular uptake. Here, we provide a closer review of clinical prospects and mechanisms of action of nanomedicines to overcome drug resistance. The significance of specific targeting towards cancer cells is debated as well.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer's disease

  • Wang, Lihua
  • Nykänen, Niko-Petteri
  • Western, Daniel|||0000-0003-3725-9553
  • Gorijala, Priyanka
  • Timsina, Jigyasha
  • Li, Fuhai
  • Wang, Zhaohua
  • Ali, Muhammad|||0000-0002-1399-6631
  • Yang, Chengran
  • Liu, Menghan
  • Brock, William
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Aguilar, Miquel
  • Pastor, Pau|||0000-0002-7493-8777
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Puerta, Raquel|||0000-0002-1191-5893
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Rutledge, Jarod
  • Oh, Hamilton
  • Greicius, Michael. D.
  • Le Guen, Yann Le
  • Perrin, Richard J.
  • Wyss-Coray, Tony
  • Jefferson, Angela
  • Hohman, Timothy J.
  • Graff-Radford, Neill
  • Mori, Hiroshi
  • Goate, Alison|||0000-0002-0576-2472
  • Levin, Johannes|||0000-0001-5092-4306
  • Sung, Yun Ju
  • Cruchaga, Carlos|||0000-0002-0276-2899
Triggering receptor expressed on myeloid cells 2 (TREM2) plays a critical role in microglial activation, survival, and apoptosis, as well as in Alzheimer's disease (AD) pathogenesis. We previously reported the MS4A locus as a key modulator for soluble TREM2 (sTREM2) in cerebrospinal fluid (CSF). To identify additional novel genetic modifiers of sTREM2, we performed the largest genome-wide association study (GWAS) and identified four loci for CSF sTREM2 in 3,350 individuals of European ancestry. Through multi-ethnic fine mapping, we identified two independent missense variants (p.M178V in MS4A4A and p.A112T in MS4A6A) that drive the association in MS4A locus and showed an epistatic effect for sTREM2 levels and AD risk. The novel TREM2 locus on chr 6 contains two rare missense variants (rs75932628 p.R47H, P=7.16×10; rs142232675 p.D87N, P=2.71×10) associated with sTREM2 and AD risk. The third novel locus in the TGFBR2 and RBMS3 gene region (rs73823326, P=3.86×10) included a regulatory variant with a microglia-specific chromatin loop for the promoter of TGFBR2. Using cell-based assays we demonstrate that overexpression and knock-down of TGFBR2, but not RBMS3, leads to significant changes of sTREM2. The last novel locus is located on the APOE region (rs11666329, P=2.52×10), but we demonstrated that this signal was independent of APOE genotype. This signal colocalized with cis-eQTL of NECTIN2 in the brain cortex and cis-pQTL of NECTIN2 in CSF. Overexpression of NECTIN2 led to an increase of sTREM2 supporting the genetic findings. To our knowledge, this is the largest study to date aimed at identifying genetic modifiers of CSF sTREM2. This study provided novel insights into the MS4A and TREM2 loci, two well-known AD risk genes, and identified TGFBR2 and NECTIN2 as additional modulators involved in TREM2 biology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Huntingtin CAG repeats in neuropathologically confirmed tauopathies, Novel insights

  • Pérez-Oliveira, Sergio|||0000-0002-3292-0501
  • Castilla-Silgado, Juan|||0000-0002-6266-8247
  • Painous, Cèlia|||0000-0002-7027-3093
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Mendez-Gonzalez, Manuel|||0000-0002-5218-0774
  • Blázquez Estrada, Marta|||0000-0003-3348-9992
  • Corte, Daniela
  • Tomás-Zapico, Cristina|||0000-0001-7823-0410
  • Compta, Yaroslau|||0000-0001-6443-0104
  • Muñoz García, José Esteban|||0000-0002-0986-1291
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Balasa, Mircea|||0000-0002-1795-4228
  • Aragonès, Gemma
  • García-González, Pablo|||0000-0003-0125-5403
  • Rosende-Roca, Maitée|||0000-0003-1778-8175
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Pastor, Pau|||0000-0002-7493-8777
  • Casa-Fages, Beatriz de la|||0000-0003-0486-3308
  • Rábano, Alberto|||0000-0001-9320-6566
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Molina-Porcel, L.
  • Alvarez, Victoria|||0000-0002-1916-2523
Previous studies have suggested a relationship between the number of CAG triplet repeats in the HTT gene and neurodegenerative diseases not related to Huntington's disease (HD). This study seeks to investigate whether the number of CAG repeats of HTT is associated with the risk of developing certain tauopathies and its influence as a modulator of the clinical and neuropathological phenotype. Additionally, it aims to evaluate the potential of polyglutamine staining as a neuropathological screening. We genotyped the HTT gene CAG repeat number and APOE-ℰ isoforms in a cohort of patients with neuropathological diagnoses of tauopathies (n=588), including 34 corticobasal degeneration (CBD), 98 progressive supranuclear palsy (PSP) and 456 Alzheimer's disease (AD). Furthermore, we genotyped a control group of 1070 patients, of whom 44 were neuropathologic controls. We identified significant differences in the number of patients with pathological HTT expansions in the CBD group (2.7%) and PSP group (3.2%) compared to control subjects (0.2%). A significant increase in the size of the HTT CAG repeats was found in the AD compared to the control group, influenced by the presence of the Apoliprotein E (APOE)-ℰ4 isoform. Post-mortem assessments uncovered tauopathy pathology with positive polyglutamine aggregates, with a slight predominance in the neostriatum for PSP and CBD cases and somewhat greater limbic involvement in the AD case. Our results indicated a link between HTT CAG repeat expansion with other non-HD pathology, suggesting they could share common neurodegenerative pathways. These findings support that genetic or histological screening for HTT repeat expansions should be considered in tauopathies.